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ABSTRACT 
 
A SYSTEMATIC REVIEW OF POST-BREAST CANCER LYMPHOEDEMA 
AND ITS TREATMENT WITH NATURAL MEDICINE.  
 
J.G. Massaro-Zygmont 
 
M.Cur. minithesis, Department of Community and Health Sciences, University of the 
Western Cape 
 
In this minithesis a systematic review of all of the available contemporary 
literature on post-breast cancer lymphoedema was undertaken.  The 
purpose of this systematic review was to search for, collate, synthesize 
and thereby provide the reader with a comprehensive, evidence-based 
account of all the available research published between 1988 and 2008 on 
the treatment of post-breast cancer lymphoedema with natural medicine. 
 
Because the large number of articles published every year across a 
plethora of biomedical journals makes it incredibly difficult for 
practitioners to keep up-to-date within their specialized areas, systematic 
reviews are particularly useful as they summarize high quality, 
contemporary scientific knowledge on a topic in one place (Antman, Lau, 
Kupelnik, Mosteller & Chalmers, 1992). One such topic on which many 
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health practitioners have a paucity of information regarding management 
and risk reduction is lymphoedema (Radina, Armer, Culbertson & Dusold, 
2004) 
 
The primary objective of this research project was to assess the effects of 
natural medicine on post-breast cancer lymphoedema in regard to 1) life 
style improvement including any signs and symptoms related to the 
condition such as heaviness, tightness, pain, ache, itch, mobility of the 
affected arm, skin texture as well as psychological symptoms like distress; 
2) arm volume changes of the affected limb; 3) adverse effects; and 4) 
modification or cessation of treatment.  
 
Several online databases were searched for articles that contain the term 
lymphoedema, lymphedema, limb swelling or "linfedema" (Spanish and 
Portuguese); thereby including all possible spellings in English, Spanish 
and Portuguese.  Relevant information was extracted and recorded in 
tabular format.  The quality of each study was analysed using a checklist, 
which was drawn up by the primary researcher and study supervisor based 
on the CONSORT guidelines (Altman, 1996). 
 
To ensure quality, only randomized controlled trials, quasi-randomized 
controlled trials or clinical trials that met the inclusion or exclusion 
criteria, reporting benefits or adverse effects of natural medicines for the 
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treatment of post-breast cancer lymphoedema were included.  In addition, 
studies had to focus on natural medicine versus placebo or routine 
treatment or no treatment as types of intervention; and participants had to 
include women of all ages that had been diagnosed with post-breast cancer 
lymphoedema.  
 
The relevant data from included studies was entered into Review Manager 
5 (Revman 5) software for meta-analysis.  The primary studies included in 
this systematic review generally suffered from small sample sizes, varied 
somewhat in their operationalisation of outcomes and the format for 
presenting results, making meta-analysis very difficult.  However, results 
suggest that sodium selenite taken orally and CYCLO 3 FORT also taken 
orally are effective in the reduction of limb volume. The results also 
suggested that aromatherapy using an intervention cream containing wheat 
germ oil and essential oils of fennel, sage, geranium, black pepper and 
juniper; and vitamin E plus pentoxifylline taken orally are not effective.  
Seeing as these results are drawn from single studies with heterogeneous 
outcome variables, they should be seen as tentative until they are 
confirmed by replication.  Gaps in the literature regarding natural 
medicine as a treatment for post-breast cancer lymphoedema were 
identified, and recommendations for further research are proposed. 
 
November 2008 
 
 
 
 
 vi
DECLARATION 
 
 
I declare that, A systematic review of post-breast cancer lymphoedema and its 
treatment with natural medicine is my own work, and that it has not been submitted 
before for any examination in any other university, and that all sources I have used or 
quoted have been indicated and acknowledged by complete reference. 
 
 
Jesica Graciela Massaro-Zygmont    November 2008 
 
 
Signed:............................... 
 
 
 
 
 vii
ACKNOWLEDGEMENTS 
 
First of all I want to thank God for His infinite love and mercy, for being with me 
every step of the way.  All the glory is to Him. 
 
I would like to thank my husband, Conrad Zygmont, for his never ending support and 
love, for being always there for me encouraging me through the process.  You are the 
greatest blessing in my life and I love you very much! 
 
I also want to thank my parents, Agustin and Vicky Massaro, despite being far away 
they have always believed in me and supported me, without them I would not have 
been able to have come this far. 
 
I would like to extend my appreciation to my supervisor, Professor Cheryl Nikodem 
for making a way for me to assist to the Cochrane systematic review and RevMan 5 
workshop and to the first lymphoedema course presented in South Africa.  
 
I would also like to express my gratitude to Professor Jane Armer, my co-supervisor 
from the University of Missouri, whom I had the pleasure meeting at the 
lymphoedema course in South Africa.  Thank you for always being so quick to 
answer my questions and for always being ready to help. 
 
 
 
 
 
 viii
Finally I would like to thank my relatives and friends in Argentina, South Africa, and 
other countries, for their prayers and continuous love.  I am grateful that you got me 
to de-stress when it was much needed and for just being there for me. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ix
CONTENTS 
 
Title Page i 
Keywords ii 
Abstract ii 
Declaration vi 
Acknowledgements vii 
 
CHAPTER 1 Introduction 1 
 1.1   Introduction 1 
 1.2   Background literature 2 
 1.3   Research problem 4 
 1.4   Research objectives 5 
 1.5   Research question 6 
 1.6   Research statement 6 
 1.7   Definitions 7 
 1.7.1   Lymphoedema 7 
 1.7.2   Primary lymphoedema 7 
 1.7.3   Secondary lymphoedema 8 
 1.7.4   Lymphatic system 9 
 1.7.5   Systematic reviews 10 
 1.7.6   Mastectomy 10 
 1.7.7   Cancer 11 
 
 
 
 
 x
 1.7.8   Breast cancer conserving surgery 12 
 1.7.9   Axillary lymph node dissection (ALND) 12 
 1.7.10   Sentinel lymph node biopsy (SLNB) 12 
 1.7.11   Oncology 14 
 1.7.12   Radiotherapy 14 
 1.7.13   Chemotherapy 15 
 1.7.14   Review Manager (RevMan) 5 15 
 1.7.15   Randomized controlled trial 16 
 1.7.16   Natural medicine 16 
 1.7.17   Aromatherapy 17 
 1.8   Research design and methodology 17 
 1.8.1   Types of studies 17 
 1.8.2   Types of participants 18 
 1.8.3   Types of interventions 18 
 1.8.4   Types of outcomes measures 18 
 1.8.5   Search strategy for identification of studies 18 
 1.8.6   Methods of the review – Validity and reliability 19 
 1.8.7   Data analysis 19 
 1.9   Relevance of the study 20 
 1.10   Ethics statement 20 
 1.11   Chapter outlines 21 
 1.12   Time line 21 
 1.13   Budget 22 
 
 
 
 
 xi
 1.14   Summary 23 
 
CHAPTER 2 Literature Review 24 
 2.1   Introduction 24 
 2.2   Anatomy 25 
 2.3   Physiology 26 
 2.4   Pathophysiology of breast cancer related lymphoedema 27 
 2.5   Incidence and prevalence of lymphoedema 28 
 2.6   Classifications of lymphoedema 29 
 2.6.1   Primary lymphoedema 30 
 2.6.2   Secondary lymphoedema 31 
 2.6.2.1   Lymphoedema associated with post-breast cancer  
               treatment 31 
 2.7   Causes of lymphoedema 33 
 2.8   Predisposing factors associated with lymphoedema 34 
 2.9   Symptoms of lymphoedema 35 
 2.10   Diagnosis of lymphoedema 35 
 2.11   Stages of lymphoedema 36 
 2.12   Treatments for lymphoedema 37 
 2.12.1   Treatments overview 37 
 2.12.2   Complete decongestive therapy (CDT) 39 
 2.12.3   Manual lymphatic drainage (MLD) and Simple  
              lymphatic drainage (SLD) 40 
 
 
 
 
 xii
 2.12.4   Intermittent pneumatic compression (IPC) 41 
 2.12.5   Surgical treatments 41 
 2.12.6   Pharmacotherapy 43 
 2.12.7   Low-level laser therapy 44 
 2.12.8   Flowave 45 
 2.12.9   Other complementary and alternative therapies 45 
 2.13   Natural medicine and lymphoedema 47 
 2.13.1   Horse chestnut seed extract 48 
 2.13.2   Selenium 49 
 2.13.3   Bromelain (from pineapple) 50 
 2.13.4   Aromatherapy 50 
 2.13.5   Vitamin E supplement 50 
 2.13.6   Mulberry leaf 51 
 2.13.7   Pycnogenol (from pine bark) and Procyanidins 51 
 2.13.8   Butcher’s broom (Ruscus aculeatus) 52 
 2.14   Post-breast cancer lymphoedema lack of information /  
           education 53 
 2.14.1   Patient’s lack of information / education 53 
 2.14.2   Health care providers’ lack of information / education 54 
 2.15   Summary 54 
 
 
 
 
 
 
 
 xiii
CHAPTER 3 Research Design & Methodology 56 
 3.1   Introduction 56 
 3.2   The Review Manager (RevMan) 5 57 
 3.3   Systematic reviews 57 
 3.4   Rational for systematic reviews 58 
 3.5   Systematic reviews as scientific research 59 
 3.6   Main features of systematic reviews 59 
 3.7   Advantages of systematic reviews 60 
 3.8   Limitations of systematic reviews 61 
 3.9   Ensuring quality of systematic reviews 62 
 3.10   Criteria for selection of studies for this review 62 
 3.11   Search strategy 67 
 3.12   Methodology quality, validity and reliability 67 
 3.13   Limitations of this systematic review 69 
 3.14   Data collection 69 
 3.15   Data analysis 70 
 3.15.1   Dichotomous data 71 
 3.15.2   Continuous data 73 
 3.16   Characteristics of included studies 74 
 3.17   Excluded studies 81 
 3.18   Summary 84 
 
 
 
 
 
 
 xiv
CHAPTER 4 Results 85 
 4.1   Introduction 85 
 4.2   Life style improvement 87 
 4.2.1   Comparison 01: post-breast cancer group 87 
 4.2.2   Comparison 02: post-cancer group 89 
 4.3   Changes in arm volume (of the affected limb) 90 
 4.3.1   Comparison 01: post-breast cancer group 90 
 4.3.2   Comparison 02: post-cancer group 92 
 4.4   Adverse effects 92 
 4.4.1   Comparison 01: post-breast cancer group 93 
 4.4.2   Comparison 02: post-cancer group 93 
 4.4.3   Comparison 01 and 02 combined 94 
 4.5   Modification or cessation of treatment 95 
 4.5.1   Comparison 01: post-breast cancer group 95 
 4.5.2   Comparison 02: post-cancer group 96 
 4.6   Summary results 97 
 
CHAPTER 5 Discussion 98 
 5.1   Introduction 98 
 5.2   Discussion 100 
 5.3   Implications for practice 102 
 5.4   Implications for future research 103 
 5.5   Conclusion 105 
 
 
 
 
 xv
BIBLIOGRAPHY  107 
 
APPENDICES  118 
 
LIST OF FIGURES 
 1.1   Primary lymphoedema of the lower limbs 7 
 1.2   Secondary lymphoedema post-breast cancer treatment 8 
 1.3   The lymphatic system 9 
 1.4   Sentinel lymph node biopsy of axillary lymph nodes 13 
 2.1   Causes of lymphoedema  33 
 4.1   Forest plot of comparison 01: changes in induration fibrosis 
         using vitamin E plus pentoxifylline 87 
 4.2   Forest plot of comparison 02: symptom improvement using 
         using aromatherapy cream 89 
 4.3   Forest plot of comparison 02: well-being using  
         aromatherapy cream 90 
 4.4   Forest plot of comparison 01: adverse effects using vitamin  
         E plus pentoxifylline of CYCLO 3 FORT 93 
 4.5   Forest plot of comparison 02: adverse effects using  
         aromatherapy cream 94 
 4.6   Forest plot of both comparison groups: adverse effects  
         using vitamin E plus pentoxifylline or CYCLO 3 FORT or  
         aromatherapy cream 95 
 
 
 
 
 xvi
 4.7   Forest plot of comparison 01: modification or cessation of 
         treatment using vitamin E plus pentoxifylline or CYCLO 3  
         FORT 96 
 
LIST OF TABLES 
 1.1   Time line for the completion of the systematic review 21 
 1.2   Proposed budget for the present systematic review 22 
 2.1   Stages of lymphoedema 36 
 3.1   Selection criteria for post-breast cancer lymphoedema 
         and its treatment with natural medicine 65 
 3.2   Comparison 01: post-breast cancer group (Cluzan et al., 
           1996) 75 
 3.3   Comparison 01: post-breast cancer group (Gothard et al., 
          2004) 76 
 3.4   Comparison 02: post-cancer group (Barclay et al., 2006) 78 
 3.5   Comparison 02: post-cancer group (Micke et al., 2003) 80 
 3.6   Excluded studies (Hutson et al., 2004) 81 
 3.7   Excluded studies (Kirshbaum, 1996) 82 
 3.8   Excluded studies (Hutson, 2004) 82 
 3.9   Excluded studies (Kasseroller, 1997) 83 
 4.1   Symptom improvement using CYCLO 3 FORT (Cluzan  
         et al., 1996) 88 
 
 
 
 
 
Chapter 1 1
CHAPTER ONE 
Introduction 
 
1.1  Introduction 
 
It is estimated that approximately 30% of breast cancer survivors develop 
lymphoedema after undergoing breast cancer treatment (Bumpers, Best, Norman 
& Weaver, 2002).  There is an urgent need for greater awareness and 
understanding of the experiences of women who have undergone breast cancer 
treatment and develop lymphoedema following the treatment.  Awareness needs 
to expand especially amongst health practitioners that appear to have a lack of 
understanding regarding the risk reduction and treatment of lymphoedema 
(Radina, Armer, Culbertson & Dusold, 2004).  In addition research suggests that 
breast cancer patients often make use of alternative or complementary medicines 
in their treatment of lymphoedema symptoms, especially in cases with heavy 
swelling, despite a lack of supporting evidence based literature documenting its 
effectiveness (Ashikaga, Bosompra, O’Brien & Nelson, 2002; Fouladbakhsh, 
Stommel, Given & Given, 2005).  It was hoped that this systematic review would 
result in a greater understanding of the management of post-breast cancer 
lymphoedema with natural remedies after meta-analyses of all the data collected 
via the defined search strategy.  
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1.2   Background literature 
 
More than two million articles get published every year in over 20,000 biomedical 
journals, which makes it impossible to keep up-to-date even within a specialized 
area.  This is why systematic reviews are so important - they help practitioners or 
anyone interested in a specific topic to keep up to date with contemporary 
information, as they include high quality literature about the relevant topic 
(Antman, Lau, Kupelnik, Mosteller & Chalmers, 1992). 
 
 
A comprehensive systematic review is often used as evidence based research to 
guide nurses and doctors in discussions before and after surgery with their patients 
and could be included in the development of information leaflets or consent 
forms.  There is an urgent need for greater awareness and understanding of the 
experiences of patients who have undergone breast cancer treatment and develop 
lymphoedema thereafter.  Many health practitioners lack the understanding of 
lymphoedema management and have little or no information on risk reduction 
related to lymphoedema (Radina et al., 2004).  This uncertainty is transferred to 
patients.  For example, a South African patient while being interviewed regarding 
the knowledge of her condition stated: “…They said the swelling would be there 
forever. I’m not expecting a bigger arm like this, but they tell me it’s going to get 
bigger, and then it is going to get bigger, then it’s going to be like burst… this 
arm will be so much blood and trickle will start…” (Ester, personal 
communication, July 2008).  This knowledge is especially important for nurses, as 
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nursing care has a major impact on the patient’s outcomes, with nurses being 
responsible for monitoring for the presence of this disease so that they can rapidly 
intervene and thus minimize the extent of the problem (Marrs, 2007). 
 
 
It is estimated that approximately 30% of breast cancer survivors develop 
lymphoedema after undergoing breast cancer treatment (Bumpers et al., 2002).  It 
is important to determine the incidence and prevalence levels of post-breast cancer 
lymphoedema.  Increases in incidence may guide clinicians to do further research, 
while a decrease may show that policies that address the problem are implemented 
successfully.  Without some statistics regarding the incidence of lymphoedema, it 
may be difficult for clinicians to empirically determine the extent of the problem 
and impossible to evaluate the effectiveness of interventions (Webb, Bain, & 
Pirozzo, 2005).  Descriptive statistics are often used by researchers to compare 
ratios across different contexts, which may give information regarding the causes 
of lymphoedema amongst groups with different environmental, treatment, co-
morbid or genetic characteristics.  Finally, although not a specific aim of the 
present study, the information generated during the literature search may also be 
useful for predicting the natural course and progression of lymphoedema 
following breast cancer treatment (Webb, Bain, & Pirozzo, 2005). 
 
 
This review is based on all obtainable literature from databases that were available 
to the reviewer concerning this topic, and it is hoped to encourage a better 
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understanding of lymphoedema in general.  Special attention is given to studies 
that are concerned with herbal and natural or homeopathic compounds to treat 
secondary lymphoedema post-breast cancer as interest in the use of 
complementary and alternative medicine (CAM) to treat ailments has grown 
among the public (Olson, 2001). 
 
 
 
1.3  Research problem 
 
Public interest in the use of natural medicines is growing, and it is therefore 
important that health care practitioners are knowledgeable of the use and efficacy 
of natural medications in the treatment of specific ailments such as lymphoedema.  
However, scientific evidenced based literature is scarce, and popular literature is 
often unscientific and/or ambiguous (e.g. Bone, 2008; Brady, no date; Brady, 
1996a; Brady, 1996b; Dharmananda, 2000; Herbs2000.com, 2008; Lymphedema 
People, 2008a; Lymphedema People, 2008b; Medifocus Health, 2008; O’Connor, 
2008; Sims, 2006).  This is especially the case in the use of natural medicines for 
the treatment of lymphoedema.  Therefore, the present study was conducted to 
provide a comprehensive, evidence-based account of information on the efficacy 
of natural medicines in the treatment of post-breast cancer lymphoedema. 
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1.4  Research objectives 
 
The primary objective of this research project was to assess the effectiveness of 
natural medicines in comparison to conventional treatment, no treatment or 
placebo for the treatment of post-breast cancer lymphoedema by doing a 
systematic review and meta analyses of the results of all the literature available to 
the reviewer. The specific objectives that were considered, in order to assess the 
effectiveness of natural medicines were: 
 
• The effects on life style improvement (including any signs and symptoms 
related to the condition such as: heaviness, tightness, pain, ache, itch, 
mobility of the affected arm, skin texture, as well as psychological 
symptoms like distress). 
• The effects on arm volume changes (of the affected limb). 
• Adverse effects. 
• Modification or cessation of treatment. 
 
 
The literature regarding post-breast cancer lymphoedema and its treatment with 
natural medicine was searched and collated in order to provide a comprehensive 
summary of contemporary knowledge on the topic.  Gaps in the literature 
regarding natural medicine as a treatment for post-breast cancer lymphoedema 
were identified, and recommendations for further research were proposed. 
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1.5  Research question 
 
What are the effects of natural medicines / therapies on quality of life (including 
signs and symptoms), arm volume changes (of affected limb), adverse effects, 
modification or cessation of treatment in post-breast cancer lymphoedema 
patients? 
 
 
 
1.6  Research statement 
 
Currently there is a lack of literature on scientific, evidence based and 
methodologically rigorous studies into the use of natural medicines as part of the 
treatment of lymphoedema.  A systematic review with meta-analysis of available 
clinical trial data allows for greater validity, reduction of systematic errors or bias, 
and greater generalizability of results across various settings.  Furthermore, it may 
result in an increased understanding of the effectiveness of natural medicines as 
part of the treatment of post-breast cancer lymphoedema for both the person 
suffering from lymphoedema and the health care worker responsible for the care. 
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1.7  Definitions 
1.7.1   Lymphoedema 
 
Lymphoedema is the “accumulation of lymph in the interstitial spaces, usually in 
the peripheral tissue, due to some interference with the lymphatic return.  Since it 
is a one-way system, this fluid has no way to get out of the tissues and 
accumulates” (Pratt, 1956, p. 1548).  It can be classified into primary or secondary 
lymphoedema (Weissleder & Schuchhardt, 2008). 
 
 
1.7.2  Primary lymphoedema 
 
Primary lymphoedema results from a genetic or congenital abnormality of lymph 
of the lymphatic system (Casley-Smith & Casley-Smith, 1992 cited by McCallin, 
Johnston, & Bassett, 2005).  See figure 1.1 below: 
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Figure 1.1: Primary lymphoedema of the lower limbs (The Jacksonville 
Lymphedema Clinic, 2005). 
 
 
1.7.3  Secondary lymphoedema 
 
Secondary lymphoedema may be caused by “trauma, such as axillary lymph node 
dissection during surgery for breast cancer, or by filariasis, which is a parasitic 
infection of the lymphatic system occurring in the tropical and equatorial parts of 
the world” (Casley-Smith & Casley-Smith, 1992 cited by McCallin, Johnston & 
Basset, 2005, p. 101).  See figure 1.2 below: 
 
Courtesy of BioCompression Systems Inc. 
Figure 1.2: Secondary lymphoedema post-breast cancer treatment (Storer, 
2006). 
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1.7.4  Lymphatic system 
 
It is described as the “systems of vessels and glands through which the lymph is 
returned to the circulation system” (Weller, 2001, p. 244).  See figure 1.3 below: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: The lymphatic system (Lymphedema Treatment Center, no date). 
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1.7.5  Systematic reviews 
 
“Systematic reviews attempt to collate all evidence that fits pre-specified 
eligibility criteria in order to answer a specific research question” (Higgins & 
Green, 2008, p. 4).  A systematic review is a selection and collection of data from 
primary studies, in which the primary studies are analysed and where the results 
may be presented in narrative form, quantitative form (using meta-analysis) or 
both.  Preference is given to randomized controlled trials over other types of 
studies for inclusion in the review (Higgins & Green, 2008; Jadad & McQuay, 
1996). 
 
 
1.7.6  Mastectomy 
 
Mastectomy is a surgical procedure that is often performed as a treatment for 
breast cancer (Gale Encyclopaedia of Cancer, 2006).  Radical mastectomy, an 
approach attributed to William Halsted, which involves the en bloc removal of the 
breast, muscles of the chest wall, and contents of the axilla was the standard 
surgical procedure for the treatment of breast cancer for much of the 20th century 
(Fisher, Jeong, Anderson, Bryant, Fisher, & Wolmark, 2002).  This approach was 
later discarded for a more moderate approach called modified radical mastectomy. 
In this approach all of the breast tissue, its overlying skin and the contents of the 
axilla nodes are removed.  The procedure is less debilitating than radical 
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mastectomy seeing as pectoral muscles are not removed, and post-operative 
oedema of the arm less likely (Schachter & Neuhauser, 1981). 
 
 
1.7.7  Cancer 
 
Cancer is a general term to describe malignant growths in tissues.  There are many 
different types of cancers.  For example, carcinoma refers to cancers of the 
epithelial tissue, while sarcoma refers to cancers of connective tissue origin, as in 
bone and muscle.  The basic aetiology of cancer remains unknown; however, 
many potential causes and contributing factors have been identified.  Some of 
these include cigarette smoking, ionizing radiation, exposure to certain chemicals 
and overexposure to the sun.  Hereditary factors also play an important part in the 
development of cancers.  A cancerous growth is one that is “not encapsulated, but 
infiltrates surrounding tissues, the cells of which it replaces by its own.  It is 
spread by the lymph and blood vessels and may lead to metastases in other parts 
of the body.  Death is caused by destruction of organs to a degree incompatible 
with life, by extreme debility and anaemia, or by haemorrhage” (Weller, 2001, p. 
69). 
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1.7.8  Breast cancer conserving surgery 
 
Breast conserving surgery is an operation that removes the breast cancer along 
with a margin of normal breast tissue around it, while attempting to conserve as 
much of the normal breast tissue as possible.  There are three main ways this 
surgery is done: lumpectomy, quadrantectomy, and segmental mastectomy 
(Breastcancer.org, 2007a).  A sentinel lymph node biopsy is often conducted on 
proximal axillary lymph nodes, which are then either removed or left intact if a 
the sentinel nodes are found to be negative. 
 
 
1.7.9  Axillary lymph node dissection (ALND) 
 
Axillary lymph node dissection (ALND) is a surgical procedure used to assess 
breast cancer and its need for further treatment (Encyclopedia of Surgery, 2007), 
and/or to take out lymph nodes from the armpit area (Breastcancer.org, 2007b).  
 
 
1.7.10  Sentinel lymph node biopsy (SLNB) 
 
Sentinel lymph node biopsy (SLNB) is a procedure in which a dye and/or 
radioactive substance is injected into the proximity of the cancer tumour and 
subsequently drains into the lymph nodes.  The first lymph node that the dye 
 
 
 
 
Chapter 1 13
comes to is called the sentinel lymph node, as it has the highest probability of 
coming into contact with cancer cells that might spread after breaking away from 
the main cancer in the breast.  Sometimes there is more than one sentinel node.  
The radioactive substance or dye makes it possible for clinicians to identify the 
sentinel lymph node, or nodes, which are then removed and checked to see if there 
are cancer cells in them (Breastcancer.org, 2007c).  Refer to figure 1.4 below: 
 
  
Figure 1.4: Sentinel lymph node biopsy of the axillary lymph nodes (National 
Cancer Institute, 2008).  
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1.7.11  Oncology 
 
Oncology is the section of science that concerns itself with the study of tumours 
(Weller, 2001). 
 
 
1.7.12   Radiotherapy 
 
Radiotherapy is the treatment of disease by radiation or radioactive isotopes 
(Weller, 2001).  It is broadly categorised into two approaches, teletherapy in 
which the source of radiation is further away from the tumour and in which X-
rays are typically used, and brachytherapy that describes approaches in which the 
source is either within or very close to the tumour and tends to utilize radioactive 
sources (Cherry & Duxbury, 1998).  In treatment of breast cancer external beam 
radiation is the type most frequently used, typically at a schedule of 50 Gy, 
delivered in 25 fractions of 2·0 Gy over 5 weeks, but research findings do suggest 
that lower doses in a smaller number of fractions could deliver the same required 
effects (The START Trialists’ Group, 2008). 
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1.7.13   Chemotherapy 
 
Chemotherapy can be loosely defined as the specific treatment of disease by the 
administration of chemical compounds that most often have cytotoxic effects 
(Weller, 2001).  The first of such compounds that could be considered the 
historical antecedent of modern chemotherapy was used from 1630 by the Jesuits 
who made a tea from the bark of the chinchona tree to treat malaria.  However, the 
advances made in the use of chemotherapy in the treatment of cancer only came 
about in the early twentieth century when Paul Ehrich coined the term 
chemotherapy to describe the use of specific drugs for the treatment of infectious 
disease and cancer (Ingwersen, 2001).  One use of chemotherapy, which is 
particularly useful in the treatment of breast cancer in women with a high risk of 
recurrence, is adjuvant chemotherapy that takes place after primary surgery has 
taken place and is targeted at micrometastases.  It is common to use a combination 
of two to five drugs together although dosage and duration depend heavily on the 
regimen. For example, six months seems adequate for a CMF (cyclophosphamide, 
methotrexate, and 5-fluorouracil) regimen, whereas three to four months would 
suffice for doxorubicin regimens (Stein, 1998). 
 
 
1.7.14   Review Manager (RevMan) 5 
 
Review Manager 5 (RevMan 5) is a software tool used to aid in the process of 
producing a systematic review.  It is a computer program developed by The 
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Cochrane Collaboration Programme intended to help authors prepare and keep up-
to-date Cochrane Systematic reviews.  This software assists in the development of 
protocols and full reviews.  Furthermore, RevMan 5 may also be used to calculate 
meta-analyses of the data entered into it, thus showing the results in a graphical 
form (The Cochrane Collaboration, 2008).  
 
 
1.7.15   Randomized controlled trial 
 
A randomized controlled trial is any experimental study in which “investigators 
randomly allocate eligible people to receive or not to receive one or more 
interventions that are being compared.  The results are assessed by comparing 
outcomes in the treatment and control groups” (Cochrane Reviewers’ Handbook 
Glossary, no page number). 
 
 
1.7.16   Natural medicine 
 
For the purpose of this thesis, natural medicine will be defined as a 
complementary and alternative medicine that uses preparations made from plants, 
herbs, vitamins or foods to prevent and treat diseases and ailments or to promote 
health and healing. 
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1.7.17 Aromatherapy 
 
Aromatherapy can be described as the therapeutic use of essential oils based on 
the perceived pharmacological, psychological or neurological effects of the 
‘active components’ of such oils.  Essential oils are effectively obtained by 
various processes of distillation that attempts to maintain them in their natural 
form.  Within the field there is a strong belief in the synergistic pharmacology of 
the chemical constituents of essential oils, and thus essential oils in their natural 
state are favoured over synthesized active components.  Examples of essential oils 
are Ambrette, Black currant, Citronella, Lavender, Myrrh, Orris and Yang 
(Schnaubelt, 1999).  Essential oils believed by some to be useful in the treatment 
of lymphedema include frankincense, grapefruit, hyssop, safflower oil and 
lavender. 
 
 
1.8   Research design and methodology 
1.8.1  Types of studies 
 
All randomized controlled trials, quasi-randomized controlled trials or clinical 
trials that met the inclusion or exclusion criteria, reporting benefits or adverse 
effects of natural medicines for the treatment of post-breast cancer lymphoedema. 
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1.8.2  Types of participants 
Women of all ages diagnosed with post-breast cancer lymphoedema. 
 
 
1.8.3  Types of intervention 
Any use of natural medicine versus placebo or routine treatment or no treatment. 
 
 
1.8.4  Types of outcomes measures 
The primary outcomes refers to any type of life style improvement such as: any 
signs and symptoms related the condition e.g. heaviness, tightness, pain, ache, 
itch, mobility of affected arm, skin texture, as well as psychological symptoms 
like distress followed by arm volume changes of the affected limb, adverse 
effects, cessation or modification of treatment. 
 
 
1.8.5  Search strategy for identification of studies 
 
The databases Blackwell Synergy, CINAHL, Cochrane Database of Systematic 
Reviews, Cochrane Controlled Trials Register, EBSCOhost, InfoTrac, JSTOR, 
PubMed, Medline, ProQuest, ScienceDirect, LILACS, Wiley InterScience, and 
Google Schoolar were searched for articles that contain the term lymphoedema, 
lymphedema, limb swelling and "linfedema" (Spanish and Portuguese); thereby 
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including all possible spellings in English, Spanish and Portuguese.  Articles 
between the year 1988 and 2008 were included for analysis.  Relevant information 
was extracted, including the quality of the study, and recorded in tabular format.  
The quality of each study was analysed using a checklist, which was drawn up by 
the study supervisor and the primary researcher based on the CONSORT 
guidelines (Altman, 1996). 
 
 
1.8.6  Methods of the review – Validity and reliability 
 
Randomized controlled trials, quasi-randomized controlled trials and clinical trials 
were selected by the reviewer for exclusion and inclusion, and were checked to 
ensure consistency and reliability by the supervisor and co-supervisor.  The data 
were carefully entered and doubled checked to ensure accuracy.  The studies that 
were not included in this systematic review were captured into a record and the 
reasons for exclusion are provided. 
 
 
1.8.7  Data Analysis 
 
Scientific articles that met the inclusion and exclusion criteria were reviewed by 
the reviewer and the supervisors for inclusion in the review.  The information was 
then entered onto Review Manager 5 (RevMan 5) software to systematically 
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meta-analyse the information.  Data analysis in this systematic review included 
both a narrative description of the results of included studies and a quantitative 
(statistical) analysis of the results wherever it was possible and/or appropriate.  
 
 
1.9  Relevancy of the study 
 
It is hoped that the results of this systematic review will help to define the effects 
of natural medicines on post-breast cancer lymphoedema patients. 
 
 
1.10  Ethics statement 
 
The study proposal was sent for ethical review to the University of the Western 
Cape Faculty of Community and Health Sciences Higher Degrees Committee and 
Senate.  Since the present study is a systematic review, it was not subject to 
certain ethical concerns such as voluntary participation and informed consent as 
other designs may be.  This systematic review will be sent to The Cochrane 
Collaboration as a scientific article for possible publication where it will be peer 
reviewed.  It is important that the reviewer makes all selection criteria for 
inclusion, exclusion and methods of analysis explicit in order to avoid bias.  These 
are clearly defined in more detail in section 3.10.  
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1.11   Chapter outlines 
 
Chapter one gives a summary outline in the form of a proposal.  Current literature 
concerning lymphoedema is discussed in chapter two.  Chapter three describes the 
methodology of the review.  In chapter four the results are given.  Chapter five 
contains the discussion of the results with conclusions and possible implications 
for future research. 
 
 
1.12   Time line 
 
Table 1.1 
Time line for the completion of the systematic review 
 
Writing proposal    June-August 2007 
Submission of proposal to higher degree  August 2007 
Approval of proposal  August 2007 
Selecting and sorting of articles   September 2007-June 2008 
Analysis of data    June - September 2008 
Formatting conclusions   September - October 2008 
Complete writing of thesis   October -November 2008 
Submission of thesis   November 2008 
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1.13   Budget 
 
Below is a breakdown of the expenses incurred in the process of completing this 
research study.  The study supervisor allocated funds for the RevMan workshop 
and Lymphoedema course, while the rest of the expenses were covered by the 
researcher. 
 
Table 1.2 
Proposed budget for the present systematic review 
 
RevMan 5 workshop R500 
Lymphoedema course R2800 
Photocopying R1000 
Printing R2000 
Stationary R500 
Internet R1200 
Petrol  R3000 
Total 11000 
 
 
The above expenditures made it possible for the reviewer to gain access to online 
journals, print the articles so that they were easy to read and mark, collate the data 
in a systematic manner, learn to use the RevMan 5 software, gain more in-depth 
knowledge regarding lymphoedema, and travel from home to the university in 
order to meet with the study supervisor and make use of the library facilities. 
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1.14  Summary 
 
In this chapter is found a short introduction of the topic of this systematic review.  
The principal objective of this review is to evaluate the effectiveness or adverse 
effects of natural medicines as a part of treatment for post-breast cancer 
lymphoedema.  
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CHAPTER TWO 
Literature Review 
 
2.1  Introduction 
 
Lymphoedema is a lifelong condition characterised by protein-rich oedema in a 
part of the body as a result of the accumulation of lymphatic fluid due to 
obstruction or abnormalities in the lymph nodes of the lymphatic system (Pratt, 
1956).  This condition may result from treatments for breast cancer, such as 
lymph node dissection, surgery and/or radiation and can be reduced in severity if 
detected early and treated.  However, it is generally under reported and under 
treated (Marrs, 2007).  Presently there is no cure for cancer related lymphedema 
(Liao, Huang, Li, Chen, Wei, Kuo, Chen & Hsu, 2004).  
 
 
The present literature review focuses on post-breast cancer lymphoedema and its 
treatment with natural medicines.  Information is included that is relevant to all 
classifications of lymphoedema, such as the incidence and prevalence in South 
Africa and some other countries, the classifications (with emphasis placed where 
post-breast cancer treatment lymphoedema is classified), the possible causes, 
predisposing factors, symptoms, diagnostic methods, stages through which a 
patient may typically progress, and all available treatments – placing emphasis on 
natural medicines as alternative/ complementary treatments. The  review will 
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however begin with a discussion of the anatomy, physiology and pathophysiology 
of breast cancer related lymphedema. 
 
 
 
2.2 Anatomy 
 
The lymphatic system consists of different vessel systems and interspersed lymph 
nodes, acting as a drainage and transport system for the body.  A diagrammatic 
representation of this system is displayed in Figure 1.3.  Initial lymphatic sinuses, 
which are endothelial ducts with an average lumen diameter of 56.0 ± 10.0 μm, 
make up the beginning of the lymphatic system.  Following on there are 
precollectors, which are sections of lymphatic vessels between the initial 
lymphatic sinuses and the collectors that contain incomplete values and 
trabeculae, creating turbulence in the lymphatic flow and thereby fostering re-
absorption and immunological properties.  These precollectors also tend to lie in 
close contact to rhythmically pulsating arterial blood vessels that in conjunction 
with muscle contractions assist lymphatic flow.  The lymph collectors are vessels 
consisting of three layers separated by sheets of elastic fibres and contain values 
interspersed at distances of between 6 to 20 mm that control the direction of flow.  
These connect seamlessly with lymphatic trunks that filter the lymph into the 
venous blood via lymphovenus anastomoses from both superficial and deep 
lymphatic systems that share various connections allowing the transport of lymph 
from distal to proximal, and also from the superficial to the deep systems and visa 
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versa.  The thoracic duct is the main collector of the lymphatic system.  Variations 
in vessel course are frequent, which explains why a functional collateral 
circulation can develop after removal of the axillary lymph nodes following breast 
cancer therapy.  The axillary lymph nodes constitute a small number of the 
roughly 600 lymph nodes distributed about the body, which receive both lymph 
and arterial vessels and can contain cross-connections between neighbouring 
lymph nodes (Zltzer, Weissleder, & Schuchhardt, 2008). 
 
 
 
2.3  Physiology 
 
The main function of the lymphatic system is to circulate interstitial fluid back 
into venous circulation.  As a part of this process water and large molecules such 
as proteins and waste are removed from the body fluids and transported back into 
the vascular system, lymphocytes and other defence cells are re-circulated, 
oedema is prevented, various nutrients that have been taken up via the bowel’s 
lymphatics are transported, and the body’s inner balance is maintained.  The three 
most important mechanisms responsible for generating and maintaining lymphatic 
flow include diffusion, filtration or re-absorption, and pinocytosis or endocytosis.  
Within this system the lymph nodes act as biological filter stations responsible for 
the concentration or dilution of lymph, cell-mediated and humoral immunity, 
storage of pigments and other agents, and for acting as an intralymphatic filter 
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between the interstitial and the blood systems (Schuchhardt, Weissleder, & 
Zltzer, 2008). 
 
 
 
2.4  Pathophysiology of breast cancer related lymphoedema 
 
Lymphoedema of the arm is the most common complication following curative 
treatment of breast cancer, and results from damage of the auxiliary lymphatic 
system by lymph node extirpation and/or percutaneous radiation therapy of the 
regional lymph drainage areas.  As a consequence the transport capacity of the 
lymphatic system is compromised and the volume of protein and water is greater 
than compensatory mechanisms can handle and a mechanical lesion results.  
Protein accumulates in the tissues with the potential of developing into 
fibrosclerosis if not treated properly, while metabolic processes in the interstitium 
are disturbed and inflammatory processes are facilitated further hampering lymph 
circulation (Weissleder & Schuchhardt, 2008). 
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2.5  Incidence and prevalence of lymphoedema 
 
The true incidence (Bicego, Brown, Ruddick, Storey, Wong, & Harris, 2006; 
Paskett & Stark, 2000) and prevalence of lymphoedema worldwide is not known 
(Ferrel & Coyle, 2001), but it is speculated that the total incidence of secondary 
lymphedema alone is more than 100 million cases.  These are mainly due to an 
infectious process known as filariasis in underdeveloped parts of the world, and 
trauma such as breast cancer treatment in developed countries.  The incidence has 
been shown to increase each year after initial breast cancer treatment (Morrell, 
Halyard, Schild, Ali, Gunderson & Pockaj, 2005), thus it is believed that an 
increase in breast cancer incidence would result in an increase in secondary 
lymphoedema (Hayes, 2008).  It is estimated that approximately 30% of breast 
cancer survivors develop lymphoedema after undergoing breast cancer treatment 
(Bumpers et al., 2002), and approximately 25% after a mastectomy, with an 
increase to 38% for those who also undergo radiation (Bicego et al., 2006; Paskett 
& Stark, 2000).  Lymphoedema can develop almost immediately after surgery or 
it could take up to 30 years for the symptoms of lymphoedema to begin, so “the 
cumulative incidence depends on the period of time over which women are 
followed and the method used to estimate incidence” (Geller, Vacek, O’Brian, & 
Secker-Walker, 2005, p. 925).   
 
 
Filariasis, classified as secondary lymphoedema (transmitted by mosquitoes), 
occurs mainly in underdeveloped countries and it is the most common type of 
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secondary lymphoedema in countries such as Brazil, several countries in the 
North of Africa, India, and South-East Asia (Zuther, 2004). 
 
 
Cancer treatment, trauma and surgery are the major causes of secondary 
lymphoedema in developed countries (Ferrell & Coyle, 2001).  For example, the 
United States have the highest incidence of secondary lymphoedema as a result of 
breast cancer surgery (Zuther, 2004), while Australia have the highest incidence 
of secondary lymphoedema due to melanoma treatment (Hayes, 2008).  
 
 
Currently there are no incidence and prevalence statistics for South Africa and 
many other countries related to lymphoedema.  Furthermore, the reviewer in her 
very thorough search could not find any research done in South Africa related to 
post-cancer lymphoedema from 1988 till 2008.  
 
 
 
2.6      Classifications of lymphoedema 
 
Lymphoedema is a lifelong condition characterised by protein-rich oedema in a 
part of the body as a result of the accumulation of lymphatic fluid due to 
obstruction or abnormalities in the lymph nodes of the lymphatic system (Pratt, 
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1956).  This condition may result from treatments for breast cancer, such as 
lymph node dissection, surgery and/or radiation (Marrs, 2007). 
 
 
Lymphoedema is commonly classified into primary or secondary lymphoedema.  
These two classifications will be discussed in more detail below. 
 
 
 
2.6.1  Primary lymphoedema  
 
Primary lymphoedema results because of a congenital of genetic abnormality 
(hyperplasia, hypoplasia, aplasia or scorosis of the lymph nodes) in structure or 
function of the lymphatic system (Morrell et al., 2005; Zuther, 1999).  These 
hereditary lymphoedema include: congenital lymphoedema, lymphoedema 
praecox, and lymphoedema tarda (Morrell et al., 2005).  If primary lymphoedema 
occurs before the patient reaches the age of 35 it is known as lymphedema 
praecox, which accounts for 83% of primary lymphedema cases, whereas if it 
occurs after the age of 35 it is known as lymphoedema tardum (Norton School of 
Lymphatic Therapy, 2008). 
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2.6.2  Secondary lymphoedema  
 
Sometimes called acquired lymphoedema, is associated with lymph node 
dissections, radiation of lymph nodes, surgery such as mastectomy, trauma and 
infections.  Secondary lymphoedema is the most common type worldwide; as 
previously stated, this is mainly due to filariasis in underdeveloped parts of the 
world, and trauma such as breast cancer treatment in developed countries. 
(Morrell et al., 2005).  
 
 
 
2.6.2.1  Lymphoedema associated with post-breast cancer treatment 
 
Lymphoedema onset following the diagnosis and treatment of breast cancer is 
usually associated with breast cancer therapy such as surgery and radiotherapy, 
but has also been linked with advanced disease from tumour compression or a 
lymphatic vessel being obstructed (Morrell et al., 2005).  It can be exacerbated by 
adjuvant radiotherapy.  Under standard protocol, patients with breast cancer 
normally receive adjuvant radiotherapy after breast conserving surgery if there is 
high risk of local or regional reappearance (Morrell et al., 2005).   
 
 
Mastectomy is the complete removal of a breast, and is often the treatment of 
choice when there is more than one site of cancer in the breast.  On the other hand, 
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when there is only one site and the cancer is under 4cm and has clear margin, 
breast-conserving surgery such as a lumpectomy can be performed.  A 
lumpectomy involves the removal of a limited amount of tissue that leaves the 
breast relatively intact and may be followed by radiation treatment 
(Breastcancer.org, 2007d). 
 
 
The true incidence of lymphoedema is not known but it is estimated that 
approximately 30% of breast cancer survivors develop lymphoedema after 
undergoing breast cancer treatment (Bumpers et al., 2002), and approximately 
25% after a mastectomy, with an increase to 38% for those who also undergo 
radiation (Bicego et al., 2006; Paskett & Stark, 2000).  
 
 
Numerous researchers cited by McCallin, Johnston, and Bassett (2005) suggest 
that newer improved surgical protocols techniques, such as sentinel lymph node 
biopsy (SLNB), may possibly reduce the incidence of lymphoedema given that 
greater numbers of lymph node removal are unnecessary if the sentinel lymph 
nodes are negative.  These preventive and early detection strategies might help 
patients from developing morbidities related to more chronic and severe 
conditions or from progressing to advanced lymphoedema stages.  It will also help 
practitioners understand the long-term impact of this progressive condition 
providing direction for future service development. 
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2.7   Causes of lymphoedema 
 
The causes of lymphoedema differ depending on the type of lymphoedema, and 
the age of onset.  Figure 2.1 below, illustrates the different causes of primary and 
secondary lymphoedema. 
 
Figure 2.1:  Causes of lymphoedema (Kerchner, Fleischer & Yosipovitch, 
2008). 
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2.8  Predisposing factors associated with lymphoedema 
 
There is divergence regarding the predisposing factors for the development of 
lymphoedema depending on age, body mass index and weight, infection and pre-
existing co-morbid conditions such as cardiovascular conditions (Morrell et al., 
2005).  In the case of cancer presence: surgical technique used, cancer site, 
radiotherapy, chemotherapy, experience of the surgeon, skin lesion and/or 
abnormality of the lymphatic system may all play a role (Hayes, 2008). 
 
 
It is important to note that there are significant racial differences in breast cancer 
incidence, mortality, and stage of disease at diagnosis (Taylor, Lamdan, Siegel, 
Shelby, Hrywna & Moran-Klimi, 2002).  In addition to being associated with 
breast cancer treatment, symptoms occurring post-treatment may be associated 
with gender and socio-demographic factors like income and ethnicity.  These 
disparities most likely result from a lack of information regarding therapeutic 
interventions, language barriers, not being able to afford rehabilitative treatment 
therapies, or lack of information on how to communicate appropriately and 
effectively with health providers (Eversley, Estrin, Dibble, Wardlaw, Pedrosa & 
Favila-Penney, 2005). 
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2.9  Symptoms of lymphoedema 
 
Radina et al., (2004) as well as Marrs (2007) cite various studies that have 
described the signs and symptoms that women usually notice as a result of 
lymphoedema.  These include swelling in the arm or fingers, which may progress 
to a pitting oedema or develop into firm, thickened skin; numbness, stiffness, or 
pain in the affected area; reduced range of motion; heaviness, aching, weakness, 
warmth or redness; fullness, decreased flexibility of limb, tighter clothing, 
tightness of rings, and skin changes such as peau d’orange appearance.  
Psychological symptoms that have been reported include changes in self-image 
and body imagine (Woods, 1993), increased psychological distress, anxiety and 
depression (Carter, 1997).  
 
 
 
2.10  Diagnosis of lymphoedema 
 
Diagnosis can be made from the clinical history, physical examination (including 
inspection and palpation), and volume measurement (can be done using a 
measuring tape and calculating the volume, water displacement volumetry and/or 
optoelectronic volumetry) mainly, but other diagnostic tests may be needed or can 
be used such as lymphoscintigraphy (isotope lymphography), lymphography 
(direct) (scarcely used as it can cause lymphatic injury), indirect lymphography, 
fluorescent microlymphography, Doppler ultrasonography, magnetic resonance 
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imaging (MRI), venous ultrasonography, venography (Ferrell & Coyle, 2001 & 
Weissleder & Schuchhardt, 2008), and computed tomography (CT) scan 
(Weissleder & Schuchhardt, 2008). 
 
 
 
2.11  Stages of lymphoedema 
 
There are three stages of lymphoedema progression, which differ in terms of the 
degree of swelling and likelihood of reversal.  These are shown in Table 2.1 
below: 
 
Table 2.1 
Stages of lymphoedema (of all causes) 
 
Stage Description Characteristics 
 
I  
Reversible lymphoedema 
-Pitting. 
-Swelling reduced with 
elevation of the swollen 
extremity. 
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II 
Spontaneously 
irreversible 
lymphoedema 
-Increased fibrous tissue 
with progressive skin 
hardening.  
-Frequent infections. 
-No pitting. 
-No reduction in swelling 
with elevation of the 
extremity. 
 
III 
 
Lymphostatic 
elephantiasis 
-Skin changes (large 
hanging skin folds, 
papillomas). 
-Association with Stewart-
Treves syndrome. 
 
(Morrell et al., 2005). 
 
 
 
2.12  Treatments for lymphoedema 
2.12.1  Treatments overview 
 
There is currently no known cure for lymphoedema, but the condition can be well 
managed with the suitable treatment.  The treatment for lymphoedema typically 
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includes combined modality approaches, therapeutic exercises, compression 
therapy, skin care and pharmacotherapy (Morrell et al., 2005).  Lately the use of 
alternative and complementary medicine has become more popular in many 
countries (MacLennan, Wilson & Taylor, 2002).  Lymphoedema should however 
not be treated with pharmacotherapy or natural supplements alone (National 
Lymphedema Network, 2008).   
 
 
Moseley, Carati and Piller (2007) presented a literature review of conservative 
therapies used for post-breast cancer including: complete decongestive therapy, 
manual lymphatic drainage, pneumatic pumps, oral pharmaceuticals, low level 
laser therapy, compression garments and bandaging, limb exercise, and limb 
elevation.  They concluded that according to the available research and literature 
complete decongestive therapy, manual lymphatic drainage, pneumatic pump, and 
laser therapy usually resulted in greater volume reductions.   
 
 
According to Myoung (2004), currently the most effective therapy used to treat 
lymphoedema seems to be complete decongestive therapy, if provided by well 
trained health practitioners. 
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2.12.2  Complete decongestive therapy (CDT) 
 
Complete decongestive therapy (CDT), sometimes referred to as complex 
decongestive physiotherapy, has two phases.  Phase 1 is a reducing phase where 
manual lymphatic drainage and compression bandages are applied, and the patient 
is educated regarding remedial exercises, skin and nail care, compression 
garments, and lymphoedema in general.  This is followed by Phase 2, which is the 
maintaining phase.  The expected outcomes of this therapy include decreasing the 
oedema, augmenting lymph drainage from the mal-functioning areas, decreasing 
subdermal fibrosis, improving the skin condition, increasing the functionality of 
the patient and encouraging the patient to persevere with a self-care program 
(National Lymphedema Network, 2008; Hayes, 2008).  
 
 
Liao and collegues (2004), using CDT with a sample of 30 women with unilateral 
upper or lower limb chronic lymphoedema after breast or pelvic cancer treatment, 
found CDT to be effective in reducing 33.2% (mean percentage) volume of the 
affected limb of all patients receiving this therapy.  The authors concluded that 
there is still a need for further research to be done on the second (maintaining) 
phase of CDT. 
 
 
Rinehart-Ayres (1998) reviewed the literature on conservative lymphoedema 
management approaches, including the compression pump (together with skin 
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care, exercise and compression garments) and CDT, and found that CDT resulted 
in a decrease in lymphoedema volume if the participants were compliant with the 
treatment programme.  
 
 
 
2.12.3 Manual lymphatic drainage (MLD) and Simple lymphatic 
drainage (SLD) 
 
MLD refers to the manual lymphatic drainage as used as part of CDT where the 
use of gentle, specific hand movements enhances the pumping of the lymph to 
areas of the lymphatic system that are not damaged. SLD is a modified version of 
MLD that is taught to women so that they may help themselves (Williams, 
Vadgama, Franks & Mortimer, 2002).   
 
 
A randomized controlled crossover study exploring the effects of MLD and SLD 
documented a decrease in limb volume and dermal thickness, an improvement in 
the quality of life of the participants in terms of emotional functioning, dyspnoea, 
sleep disturbances, and an improvement in sensations such as pain and heaviness 
that were associated with MLD (Williams, et al., 2002). 
 
 
 
 
 
 
 
Chapter 2 41
2.12.4  Intermittent pneumatic compression (IPC) 
 
This method of treatment can be used as an adjunct to other methods.  It entails 
placing the extremity affected by lymphoedema into an inflatable machine.  This 
machine works together with an air compression pump, inflating and deflating 
from distal to proximal creating a compression gradient.  There are risks when 
using this treatment, such as developing a fibrosclerotic ring obstructing the 
lymph flow even more and displacement of the lymphoedema to the proximal 
limb, nearby trunk or genitalia (National Lymphedema Network, 2008; Hayes, 
2008).  
 
 
A randomized, prospective study evaluating the effectiveness of IPC and CDT 
concluded that IPC, when use together with CDT, increases the positive 
therapeutic response (Szuba, Achalu & Rockson, 2002).  
 
 
 
2.12.5  Surgical treatments 
 
Surgical treatments include: debulking, excisional operations, liposuction and 
lymphatic reconstruction.  These surgeries have been “advocated… to reduce the 
weight of the affected limb, to help minimize the frequency of inflammatory 
attacks, to improve cosmetics, and to potentially reduce the risk of secondary 
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angiosarcoma” (National Lymphedema Network, 2008, p. 3).  The literature is 
very ambiguous regarding these treatment modalities.   
 
 
A number of studies regarding the use of liposuction, sometimes in combination 
with CDT, resulted in very encouraging results (Brorson & Svensson, 1997; 
Brorson, 2000; Brorson, Ohlin, Olsson, Langstrom, Wikilund & Svensson, 2006), 
with Borson (2000) reporting complete reduction of the excess volume at times. 
 
 
Microsurgical lymphatic-venous anastomoses were suggested to be the treatment 
of choice for patients that are not very responsive to non-surgical treatments 
(Campisi & Boccardo, 2004). 
 
 
Campbell & Harkin (2008) suggested debulking surgical procedures in the case of 
an intractable case of lower limb lymphoedema in which the patient requested 
amputation of the limb. 
 
 
According to the National Lymphedema Network (2008) these surgical treatments 
are not curative methods, involve great risks, and are not used as a treatment of 
choice. 
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2.12.6  Pharmacotherapy 
 
Diuretics and corticosteroids used solely to treat lymphoedema are harmful and 
should not be used unless an associated condition requires its use (Bruns, Micke, 
& Bremer, 2003; National Lymphedema Network, 2008). 
 
 
Benzopyrones such as coumarin, hydroxyethylrutin, and flavonoid derivates such 
as diosmin have been tested in research studies.  Coumarin and flavonoids 
produce long-term problems (Bruns, Micke, & Bremer, 2003).  Courmarin was 
found to produce liver toxicity and so its use has been stopped in some countries.  
Hydroxyethylrutin has been shown to be of advantage to better skin softening 
(National Lymphedema Network, 2008).  While Daflon 500 (a combination of 
diosmin and hesperidin), which is used widely in equatorial regions of the world 
to treat lymphoedema, has only been tested using animal models and “appears to 
result in a reduction of microvascular permeability and increase thoracic duct 
pumping” (National Lymphedema Network, 2008, p. 3).  A cochrane systematic 
review of the effectiveness of Benzopyrones in the management of lymphoedema 
concluded that their effectiveness could not be proven from the current trials thus 
further research needs to be conducted (Badger, Preston, Seers & Mortimer, 
2008). 
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2.12.7  Low-level laser therapy 
 
Low-level laser therapy is a laser therapy that uses low level milli-watts and 
seems to have positive results on cells and tissues, such as promoting 
lymphangiogenesis, motivating lymphatic motoricity, and encouraging the 
immune system (Carati, Anderson, Gannon & Piller, 2003). Piller and Thelander 
(1998) studied the effectiveness of low level laser therapy in post-breast cancer 
lymphoedema patients and followed their outcomes over a period of two and a 
half years.  Their findings showed that this therapy decreases oedema volume, and 
improves skin texture.  Patients reported improved quality of life regarding to 
pain, tightness, heaviness, cramps, pins and needles, and mobility of the affected 
arm. 
 
 
Although there is a paucity of research available on this treatment, the studies that 
have been conducted show encouraging results related to volume reduction.  
Further research needs to be conducted (Hayes, 2008; Kaviani, Fateh, Yousefi 
Nooraie, Alinagi-Zadeh & Ataie-Fashtami, 2006). 
 
 
 
 
 
 
 
 
 
Chapter 2 45
2.12.8   Flowave 
 
“Flowave is a machine that uses …low frequency sound waves like infrasound... 
(amplitude between 12 and +12 Volts)… to influence interstitial proteins in 
lymphoedema… It mechanically stimulates the lymphatic ways and it acts in the 
treated area through means of a molecular activation” resulting in more easily 
drained interstitial proteins by the lymphatic system (Ricci, 2005, p. 33). 
 
 
Research suggests that Flowave treatments stimulate the lymphatic fluid 
movement, activate interconnected limb lymph nodes and decreases derma back 
flow (Ricci, 2005).  Limited evidence based research can be found regarding this 
treatment modality thus further scientific research needs to be done to continue 
evaluating the effectiveness of this treatment for the management of 
lymphoedema.  
 
 
 
2.12.9  Other complementary and alternative therapies 
 
Some other complementary and alternative therapies lack research but have been 
proposed as somewhat aiding the reduction of lymphoedema.  These include 
ultrasound therapy, hyperbaric oxygen therapy, microwave therapy, acupuncture 
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and moxibustion, magnetic fields, vibration, hyperthermia and natural medicines / 
therapies.  
 
 
Alem & Gurgel (2008) suggest that acupuncture after breast cancer surgery is 
related to improvements in movements of the shoulder amplitude, symptoms such 
as heaviness and tightness and the extent of lymphoedema.  Further research 
needs to be done to clarify if the results were due to the natural evolution and 
history of lymphoedema or acupuncture itself. 
 
 
Natural medicines that have been researched regarding their role in alleviating 
some of the symptoms of lymphoedema include horse chestnut, selenium, 
bromelain (from fresh pineapple) (National Lymphedema Network, 2008), 
aromatherapy (Barclay, Vestey, Lambert & Balmer, 2006; Hayes, 2008; 
Kirshbaum, 1996), vitamin E supplements (Gothard, Cornes, Earl, Hall, 
MacLaren, Mortimer, Peacock, Peckitt, Woods & Yarnold, 2004 & Hayes, 2008), 
mulberry leaf (Hayes, 2008), Butcher’s broom (Ruscus Aculeatus), Hesperidin 
(from citrus) (Cluzan, Alliot, Ghabboun & Pascot, 1996), and pycnogenol (from 
pine bark) (Hutson, Love, Cleary, Anderson, Vanummersen, Morgan-Meadows & 
Doran 2004).  The effectiveness of these natural agents will be explored further in 
section 2.10. 
 
 
 
 
 
Chapter 2 47
Research suggests that breast cancer patients often make use of alternative or 
complementary medicines in their treatment of lymphoedema symptoms, 
especially regarding the treatment of swelling, despite a lack of supporting 
evidence based literature documenting its effectiveness (Ashikaga et al., 2002; 
Fouladbakhsh et al., 2005).   
 
 
 
2.13   Natural medicine and lymphoedema 
 
Due to the increasing attention being paid to complementary and alternative 
medicine (Gaskil, 2001), nurses are obliged to become more knowledgeable 
regarding natural medicines and therapies in order to evaluate their use, and 
educate patients (Mick, 2008).  
 
 
Natural medicines / therapies thought to be used complementarily or alternatively 
for the treatment of lymphoedema include horse chestnut seed extract, which 
appears to present encouraging benefits (Ody, 1993 & Leung, 2003 cited by 
National Lymphedema Network, 2008); selenium, which has had mixed benefits 
in lymphoedema associated with radiation (Ody, 1993, Leung, 2003 & Hoffman, 
1997 cited by National Lymphedema Network, 2008; Micke, Bruns, Mucke, 
Shaffer, Glatzel, DeVries, Schonekaes, Kisters & Buntzel, 2003); bromelain, 
which is a “natural diuretic found in fresh pineapple” (Cirelli, 1962, Seligman, 
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1969, Schafer, 1985 & Kelly, 1996 cited by National Lymphedema network, 
2008, p. 3.) thought to be beneficial but more research is necessary (National 
Lymphedema Network, 2008); aromatherapy (Barclay et al., 2006; Kirshbaum, 
1996) and vitamin E supplements that have been mentioned in a small number of 
studies.  Mulberry leaf (Hayes, 2008), pycnogenol (from pine bark) has been 
suggested to be somehow effective for the treatment of lymphoedema (Hutson, 
Love, Cleary, Anderson, Vanummersen, Morgan-Meadows & Doran 2004) as 
well as butcher’s broom (Ruscus Aculeatos) and hesperidin (found in citrus such 
as orange) (Cluzan, et al., 1996).  Some of these natural medicines have been 
suggested by popular literature, which is often unscientific and ambiguous, and 
for those that have been scientifically researched, there is a dearth of clinical 
trials, thus for all of these natural elements further research needs to be done.  
 
 
 
2.13.1   Horse chestnut seed extract 
 
Horse chestnut seed extract is assumed to strengthen the tissues of the lymph 
vessels capillaries (O’Connor, 2008) and decrease venous capillary permeability 
(Brady, no date & National Lymphedema Network, 2008). Horse chestnut seed 
extract can be administered as an oral tincture, as tablets (20 mg or 50 mg), or as a 
topical gel (Suter, Bommer, & Rechner, 2008). 
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A study evaluating the use of horse chestnut for the treatment of lymphoedema 
has been completed, but the results are not currently available.  Further 
information regarding their findings and the data itself was requested from the 
author of this study via email.  The response was that the results were not going to 
be published as the researcher did not find dramatic benefit from horse chestnut 
seed extract in the treatment of lymphoedema (P. Hutson, personal 
communication, August 18, 2008). 
 
 
 
2.13.2   Selenium 
 
This biological element is believed to act as a toxicity antagonist in chemotherapy 
and radiation therapy (Hayes, 2008).  Selenium has shown encouraging results in 
radiation-induced lymphoedema, with a recommended dosage ranging between 
800 - 1000μg daily for the first week, followed by a dosage reduction to about 300 
- 500μg selenium daily for the remaining weeks (Bruns, Micke & Bremer, 2003; 
Kasseroller, 1997). It is commonly administered using a sterile solution of sodium 
selenite in drinking ampules of 100μg selenium in 2ml of isotonic solution (Bruns 
et al., 2003). 
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2.13.3   Bromelain (from pineapple) 
 
Bromelain is thought to aid in the breaking down of proteins, thus reducing 
inflammation.  It helps antibiotics to treat infections such as cellulites (O’Connor, 
2008), and has diuretic effects (National Lymphedema Network, 2008).  
 
 
 
2.13.4   Aromatherapy 
 
Aromatherapy, involving the use of essential oils, is believed to improve the 
functioning of the immune system and thus the lymphatic system. Complementing 
CDT, aromatherapy is thought to improve the quality of life of patients suffering 
with lymphoedema (Sims, 2006). The essential oils used in aromatherapy, such as  
fennel, sage, geranium, black pepper and juniper, are often administered using a 
self-massage cream. 
 
 
 
2.13.5   Vitamin E supplement 
 
Vitamin E (dl-alpha tocopheryl acetate) effectiveness to treat, as an alternative 
medicine, arm lymphoedema was researched in a randomized controlled trial. The 
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findings suggested that vitamin E does not benefit this condition, failing to 
demonstrate efficacy. In clinical trials dl-alpha tocopheryl acetate has been 
administered at a dosage of 500mg twice a day orally (Gothard, Cornes, Earl, 
Hall, MacLaren, Mortimer, Peacock, Peckitt, Woods, & Yarnold, 2004).  
 
 
2.13.6  Mulberry leaf 
 
Mulberry leaf is a natural component that seems to have a diuretic property 
(Andallu et al., 2001).  Mulberry leaf has been used as complementary medicine 
in the treatment of lymphoedema due to filariasis (Wang, Liu, & Chen et al., 1990 
cited by Hayes 2008).  Mechanisms behind its potential treatment are unclear and 
thus further research is needed (Hayes, 2008). Administration is often by means of 
an injection of mulberry leaf extract. 
 
 
 
2.13.7  Pycnogenol (from pine bark) and Procyanidins 
 
Pycnogenol is extracted from French maritime pine tree and procyanidins are 
found in grape seed extracts.  Their effectiveness seems to arise due to “either 
stabilizing the collagenous subendothelial basal membrane or scavenging the free 
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radicals, or by a combination of these activities” (Brady, no date, p. 4-5).  Thus, 
the possible benefits seem to be reductions in swelling (Cancer.org, 2007).   
 
 
Two studies evaluating the use of pycnogenol for the treatment of lymphoedema 
have been completed but the results are not currently available.  Further 
information was requested from the authors of these studies regarding their 
findings and the data itself.  One of the authors responded that the data was not 
going to be published and that they did not find dramatic benefits from 
pycnogenol in the treatment of lymphoedema (P. Hutson, personal 
communication, August 18, 2008). In some instances Pycnogenol has been 
administered orally over a period of 8 weeks using 50 mg capsules, 3 times daily 
for a total of 150 mg daily, while it is also common for the dosage the be set at 
300mg daily (Cesarone et al., 2006; P. Hutson, personal communication, August 
18, 2008). 
 
 
2.13.8  Butcher’s broom (Ruscus aculeatus) 
 
Butcher’s broom is an aromatic, diuretic, mildly laxative herb that is taken orally 
and is believed to reduce inflammation, increase perspiration, and constrict the 
veins (Ageless, 2008).  A double-blind, placebo-controlled trial of butcher’s 
broom extract (Ruscus aculeatus) in combination with manual lymphatic drainage 
demonstrated a significant reduction of the limb volume (Bone, 2008).  
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2.14 Post-breast cancer lymphoedema lack of information / 
education 
2.14.1  Patient’s lack of information / education 
 
Several studies have shown that many patients at risk of developing lymphoedema 
after breast cancer treatment report that they did not receive adequate education 
regarding lymphoedema before and at the time of surgery and did not have 
enough knowledge about effective treatments (Ridner, 2006; Radina et al., 2004), 
such as compression decongestive physiotherapy involving manual lymphatic 
drainage, skin care, compression and exercises which decrease the volume of the 
limb (Radina et al., 2004).  Literature reports that patients suffering from this 
condition feel discontent towards their health providers, as they believe that their 
care givers are not well informed and trained about this condition (Ridner, 2006). 
A South African patient while being interviewed regarding the knowledge of her 
condition stated: “…They said the swelling would be there forever. I’m not 
expecting a bigger arm like this, but they tell me it’s going to get bigger, and then 
it is going to get bigger, then it’s going to be like burst… this arm will be so much 
blood and trickle will start…” (Ester, personal communication, July 2008).  This 
demonstrates the lack of adequate education regarding lymphoedema hence the 
need of more awareness of this condition.  
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2.14.2  Health care providers’ lack of information / education 
 
Radina et al., (2004) argue that the lymphoedema incidence is so high in part 
because most health care providers do not receive appropriate, formal training 
about the risk of lymphoedema, risk reduction, and treatment.  This results in a 
worldwide lack of education about the symptoms of lymphoedema, leading to late 
diagnosis and inadequate treatment that is evident because of the lack of treatment 
centres, certified lymphoedema therapists, and other professionals prepared to 
treat lymphoedema (Marrs, 2007).  Quality nursing care has a big impact on 
patient’s outcomes in regard to lymphoedema.  Nurses can be proactive in patient 
education, thus they should have the appropriate knowledge about this condition.  
They should monitor for the presence of this disease so that they can rapidly 
intervene and thereby minimize the extent of the problem (Lomas, 2008; Marrs, 
2007). 
 
 
 
2.15  Summary 
 
In sum, while there are an abundant variety of treatment methods available for the 
treatment of lymphoedema, the growing popularity of some natural medicines 
does not seem to be supported by the available literature, while others such as 
CDT seem more empirically based.  However, in light of the lack of research, and 
confusion regarding efficacy, more information is needed regarding the 
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effectiveness of natural medicines in the treatment of post-breast cancer 
lymphoedema.  This systematic review may help to clarify the efficacy of natural 
medicines in the treatment of post-breast cancer treatment lymphoedema. 
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CHAPTER THREE 
Research Design & Methodology 
 
3.1  Introduction 
 
Research is essential to promote high quality, up-to-date health care.  The research 
presented here is best described as a systematic review, which involves “an 
overview of primary studies that used explicit reproducible methods” 
(Greenhalgh, 1997, p. 672).  Systematic reviews are recognized as one of the most 
valuable and reliable research tools to aid the practice of evidence-based health 
care (Sleep & Clark, 1999, Lemmer, Grellier & Steven, 1999 cited by Muntanga, 
2004). 
 
 
Systematic reviews are a scientific investigation method or design that follow a 
research process with a previously prepared methodology (Cook, Mulrow & 
Heynes, 1997).  This method recognizes the vast quantity of existing research and 
converts the findings of multiple, primary, high quality studies into a complete 
summary of many studies on the same topic.  This helps health practitioners, or 
anyone interested in a specific topic, to keep up to date with contemporary 
information and aids them in making informed decisions while circumventing the 
need to search and read through large amounts of data (Antman et al., 1992; 
Cook, Mulrow & Heynes, 1997; Greenhalgh, 1997; Lyman & Djulbegovic, 2005). 
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Some systematic reviews use meta-analysis, considered to be a “building block of 
evidence-based practice” (Mutanga, 2004, p. 28).  Meta-analysis is a statistical or 
mathematical method that uses combined information from two or more primary 
studies and summarizes the results (Greenhalgh, 1997; Higgins & Green, 2008; 
Lyman & Djulbegovic, 2005).  
 
 
 
3.2   The Review Manager (RevMan) 5  
 
Review Manager 5 (RevMan 5) is a software tool used to aid in the process of 
producing a systematic review.  This computer programme is provided by the 
Cochrane Collaboration programme and is intended to help authors prepare and 
maintain up-to-date Cochrane systematic reviews.  This software assists in the 
development of protocols and full reviews.  Furthermore, RevMan 5 may also be 
used to conduct meta-analyses of the data entered into it, allowing for easy 
viewing of the results in a graphical format (The Cochrane Collaboration, 2008).  
 
 
 
3.3  Systematic reviews 
 
“Systematic reviews attempt to collate all evidence that fits pre-specified 
eligibility criteria in order to answer a specific research question” (Antman, 1992 
 
 
 
 
Chapter 3 58
cited by Higgins & Green, 2008, p. 4).  A systematic review is a collection and 
selection of data from primary studies, in which these primary studies are 
analysed and their results presented in either narrative form, quantitative form 
(using meta-analysis), or both. 
 
 
Researchers generally prefer to include randomized controlled trials in their 
reviews as these are considered to be of higher quality (Higgins & Green, 2008; 
Jadad & McQuay, 1996). 
 
 
 
3.4   Rationale for systematic reviews 
 
More than two million articles in over 20,000 biomedical journals get published 
every year, which makes it impossible to keep up to date even within a specialized 
area.  This is why systematic reviews are so important – they provide a complete 
summary of many studies on the same topic, helping health practitioners or 
anyone interested in keeping up to date, or making informed decisions regarding a 
specific topic, to avoid having to sift through large amounts of data, while 
accessing contemporary high quality literature about the relevant topic from one 
source (Antman et al., 1992; Cook, Mulrow & Heynes, 1997; Greenhalgh, 1997).  
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3.5   Systematic reviews as scientific research 
 
A systematic review is a scientific investigation method in itself that follows a 
research process with a previously prepared methodology.  This method of 
research, instead of using a sample of participants as a source of data, makes use 
of a sample of primary studies as a source of data.  Selection criteria of inclusion 
and exclusion of possible studies is delineated prior searching and collecting all 
possible relevant data.  After collecting the data the studies are evaluated for 
inclusion and exclusion using the selection criteria tool.  Following this, the 
relevant information is then extracted, synthesized, analysed, and the results are 
presented in narrative form, quantitative form (using meta-analysis), or a 
combination of both (Cook, Mulrow & Heynes, 1997). 
 
 
In order to ensure the quantitative rigidity and quality of the results obtained, 
randomized controlled trials are preferred over other study designs for inclusion in 
systematic reviews (Higgins & Green, 2008; Jadad & McQuay, 1996).  
 
 
 
3.6  Main features of systematic reviews 
 
According to Higgins & Green (2008), the main features of a systematic review 
include: the objectives of the study; selection criteria for the inclusion and 
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exclusion of studies; a precise and clear methodology that can be reproduced; a 
vast systematic search locating all the possible studies that could meet the 
selection criteria; included studies have to be assessed with regards to the validity 
and reliability of their findings; and a summary, in a systematic arrangement, 
presenting the characteristics and findings of included studies.  
 
 
 
3.7  Advantages of systematic reviews 
 
This type of research design is advantageous in its ability to: 
 
“resolve conflicting evidence, address questions where clinical 
practice is uncertain, to explore variations in practice, to 
confirm the appropriateness of current practice or to highlight 
a need for future research… to summarize and help people to 
understand the evidence… [and to] help people make practical 
decisions about health care” (Higgins & Green, 2008, p. 5).  
 
 
Furthermore systematic reviews limit bias in identification and exclusion of 
studies due to their explicit methods of selection criteria.  Meta-analysis increases 
the accuracy of the overall result, and different studies’ results can be combined to 
 
 
 
 
Chapter 3 61
establish generalisability of the findings and reliability of results (Greenhalgh, 
1997). 
 
 
 
3.8  Limitations of systematic reviews 
 
Systematic reviews are limited by the quality of the primary studies from which 
conclusions are drawn.  The results of studies may be limited by factors such as 
small sample sizes, insufficient statistical power, moderate or weak effect sizes 
and other such factors, so identification of good quality studies by using selection 
criteria for inclusion or exclusion of studies is key to ensure valid and reliable 
results of the systematic review.  Sometimes this might not be possible as editors, 
due to publication bias, do not publish specific findings (Muntanga, 2004).  
 
 
Systematic reviews are also limited to the experience of the authors in measuring 
risk of bias in inclusion of studies, collecting studies and data, hunting omitted or 
unpublished data, analysing data and interpreting the results (Higgins & Green, 
2008).  
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3.9  Ensuring quality of systematic reviews 
 
It is very important to ensure that authors of systematic reviews have appropriate 
training and experience.  This can be achieved by attending relevant training 
courses.  Consultation and involvement with other reviewers regarding the 
inclusion or exclusion of studies is strongly advised and sometimes required as 
well as consultation and involvement with relevant practitioners and consumers 
for input in other areas of the review.  Furthermore, to ensure a good quality 
systematic review it is important to formulate a research question that is 
answerable, well-structured and focused, as this will aid in the crucial aspect of 
systematic reviews - being the preparation of the selection criteria for inclusion 
and exclusion of studies, which in turn will guide the study and show how and 
what results to present.  It is also important to seek for further assistance regarding 
missing or unpublished data or any other doubts to clarify the quality of the 
primary studies (Higgins & Green, 2008).  
 
 
 
3.10  Criteria for selection of studies for this review  
 
The selection criteria for inclusion of prospect studies in the present systematic 
review were guided by the research question, namely:  What are the effects of 
natural medicines/therapies on quality of life (signs and symptoms), changes in 
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arm volume (of the affected limb), adverse effects, modification or cessation of 
treatment in post-breast cancer lymphedema women?   
 
 
The following aspects were considered in this study: 
 
 
Types of studies 
All randomized controlled trials, quasi-randomized controlled trials or clinical 
trials that compared the use of natural medicine versus placebo or routine 
treatment or not treatment.  Selected studies for inclusion should report benefits or 
adverse effects of natural medicines for the treatment of post-breast cancer 
lymphoedema.  
 
 
Types of participants 
The types of participants included in the studies forming part of this systematic 
review were women of any age diagnosed with any stage of post-breast cancer 
lymphoedema who were using natural medicine to treat the existing signs and 
symptoms of secondary lymphoedema. 
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Types of intervention 
Any intervention that made use of natural medicine versus placebo or routine 
treatment or no additional treatment, were included in the review.  A list of 
possible natural medicine interventions include: 
 
 
Horse chestnut seed extract 
Pycnogenol (from French maritime pine bark three) & Proacyanidins 
Bromelain (from fresh pineapple) 
Butcher’s broom (Ruscus Aculeatos) 
Hesperidin Methyl Cholcone (from citrus) 
Selenium 
Mulberry leaf 
Aromatherapy creams or oils 
Vitamin E supplement 
 
 
Types of outcomes measures 
The primary outcomes are: 
1 Perceived improvements in the domain of life style (this includes any 
physical signs and symptoms related to the condition such as heaviness, 
tightness, pain, ache, itch, mobility of affected arm, and skin texture, as 
well as psychological symptoms like distress)  
2 Perceptible changes in arm volume (of the affected limb) 
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3 Adverse effects 
4 Modification or cessation of treatment 
 
 
A summary of the above in graphic form including the search strategy are show in 
Table 3.1 below. 
 
Table 3.1  
Selection criteria for post-breast cancer lymphedema and its treatment with 
natural medicine 
 
Selection criteria 
Question 
What are the effects of natural medicines/therapies on quality of life (signs and 
symptoms), changes in arm volume (of the affected limb), adverse effects, 
modification or cessation of treatment in post-breast cancer lymphoedema women? 
Eligibility 
Interventions  Outcomes  Participants  Study type 
Natural medicines / 
therapies vs. placebo or 
conventional treatment, 
or no treatment. 
Life style 
improvement, 
adverse effects, 
modification or 
cessation of 
treatment. 
Post-breast 
cancer 
lymphoedema 
women. 
Randomized 
controlled trials, 
quasi-
randomized 
controlled trials 
and clinical 
trials. 
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Search 
Strategy  
 
 
 
 
 
 
 
 
 
Natural medicine 
Natural therapy 
Naturopathy 
Botanic medicine 
Aromatherapy 
Nutritional sup. 
Vitamin/s 
Herb/s 
Homeopathy 
Allopathy/ 
Allopathic Medicine/ 
Therapy 
Alternative Medicine/ 
Therapy  
Specific names such as: 
ginger tea, sweet clover 
ointment, horse chestnut, 
Butcher’s broom, 
Heperidin, bromelain, 
selenium, pycnogenol, 
pine bark, mulberry leaf. 
Index and free text search for: 
Secondary LE 
Post breast cancer LE 
Same as above. 
 
 
 
 
 
 
 
Chapter 3 67
3.11  Search strategy 
 
The databases Blackwell Synergy, CINAHL, Cochrane Controlled Trials 
Register, Cochrane Database of Systematic Reviews, EBSCOhost, InfoTrac, 
JSTOR, PubMed, Medline, ProQuest, ScienceDirect, LILACS, Wiley 
InterScience and Google Scholar were searched for articles that contain the term 
lymphoedema, lymphedema, limb swelling and “linfedema” (Spanish and 
Portuguese); thereby including all possible spellings in English, Spanish and 
Portuguese.  Articles between the years 1988 and 2008 were included for analysis.  
Relevant information was extracted, including the quality of the study, and 
recorded in tabular format.  The quality of each study was analysed using a 
checklist, based on the CONSORT guidelines (Altman, 1996) that was drawn up 
by the review supervisor and the primary reviewer. 
 
 
 
3.12  Methodology quality, validity and reliability 
 
In order to ensure competence the reviewer received training in the Cochrane 
Review method for developing a systematic review, Review Manager 5 
(RevMan5), and attended a two week lymphoedema training course.  The 
Cochrane and RevMan courses were beneficial for developing familiarity with the 
approach and methods of systematic review, while the lymphoedema course gave 
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the researcher a better understanding of the contemporary treatment methods 
being used to manage this little known condition.  
 
 
Randomized controlled trials, quasi-randomized controlled trials and clinical trials 
were rigorously searched, based on all obtainable studies from databases that were 
available to the reviewer.  Other studies that seemed to be adequate for this thesis 
but that were not available in the databases were requested through the inter-
library loan division at the University of the Western Cape library so that they 
could be obtained either locally or from international sources.  The studies had to 
meet the selection criteria and were concerned with herbal and natural or 
homoeopathic compounds to treat secondary lymphoedema post-breast cancer.  
The studies were selected by the reviewer and overseen for exclusion and 
inclusion by the supervisor and co-supervisor; these were also checked to ensure 
accuracy, consistency and reliability.  The information was then entered into the 
Review Manager 5 (Revman 5) software package to systematically meta-analyze 
the information.  The studies that were not included in this study were captured 
into a table and the reasons for exclusion were provided.  
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3.13  Limitations of this systematic review 
 
As for all systematic reviews, this review is limited by the quality of the primary 
studies from which conclusions are drawn.  The results of studies may be limited 
by factors such as small sample sizes, insufficient statistical power, moderate or 
weak effect sizes and other such factors, so identification of good quality studies 
by using selection criteria for inclusion or exclusion of studies is key to ensure 
valid and reliable results of the systematic review.  Sometimes this might not be 
possible as editors, due to publication bias, do not publish specific findings 
(Muntanga, 2004).  
 
 
This review may also be limited by the experience of the reviewer in measuring 
risk of bias in inclusion of studies, collecting studies and data, hunting omitted or 
unpublished data, analysing data and interpreting the results (Higgins & Green, 
2008).  
 
 
 
3.14  Data collection 
 
An extensive search was conducted based on all obtainable literature from 
databases that were available to the reviewer.  If potential studies were not 
available in the databases they were requested through inter-library loan to be 
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sourced either locally or internationally.  The outcome of this rigorous search was 
to find primary studies that would meet the selection criteria for inclusion.  Once 
the primary studies were selected, relevant data from each study was taken 
separately and entered into a specially designed data collection sheet.  Finally 
appropriate data was entered into the Review Manager 5 for analysis.  
 
 
 
3.15  Data analysis 
 
The RevMan 5 software package was used in this systematic review for statistical 
analysis.  Data was extracted from studies that met the selection criteria and put 
into a specially designed collection sheet.  From here the appropriate data was 
entered into the RevMan 5 software to undergo statistical analysis.  This software 
is designed to process the data and present the results in a chart using both 
graphical and a tabular format.  Where it was inappropriate to enter the 
information into RevMan 5, results were presented in a narrative form.  
 
 
RevMan 5 produces the results of the analysis in a standard format that makes use 
of columns of text for nominal data, as well as in the form of a forest plot and 
blobbograms.  The first column always displays the study identifier/s.  The 
information represented in the next few columns is determined by the type of data 
used.  Where dichotomous data were used one format for analysis and results 
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were used, and where continuous data another.  These are described, in turn, in 
sections 3.15.1 and 3.15.2 respectively.  The foot of the chart produced provides 
the same data for both data types.  First a summary of the events that occurred in 
each column, or event are given, and then the heterogeneity test is stated.  For this 
review tests for heterogeneity were not applicable.  Finally, the last row of the 
summary chart presents the test for overall effect, Z statistic, and its associated p-
value (Boltman, 2005). 
 
 
 
 
3.15.1   Dichotomous data 
 
For dichotomous data the Mantel-Haenszel statistical method using a fixed effect 
model and relative Risk Ratio (RR) effect measure were used.  In this case, the 
second and third columns display the number of events of a particular outcome 
(e.g. adverse effects) with the total sample size for the associated group.  This data 
is presented for both the intervention / experimental group (natural medicine) and 
control group (placebo).  The next column presents the weight that each study (in 
percentage form) contributed to the overall analysis.  Thereafter, the next column 
contains the RR and confidence interval.  The confidence limits are presented in 
square brackets and represent the range that the RR values can be inferred, or 
expected, to take in the population.  The level used in this systematic review was 
95%, meaning that there is a 95% chance that a RR collected from the population 
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would fall within this range.  The RR ratio is presented first and represents the 
ratio of the risk of the outcome occurring in the experimental group divided by the 
risk of the outcome occurring in the control group. If the RR is approximately 
equal to one, or if the confidence interval includes one, then there is no significant 
difference in outcome between those groups who received natural medicine and 
those who received placebo as part of their treatment.  If the RR is greater than 
one, and the CI is positive and does not include one, then the outcome event is 
more likely to occur among patients in the natural medicine group compared to 
those in the control group.  Finally, if the RR is less than one, and the CI lies 
below one and does not include one, then the outcome events are significantly less 
likely to occur in the natural medicine group than they are in the control group.  
The RR is comparable to odds ratios when control intervention risks are low and 
effects are small, but differ considerably as these increase (Higgins & Green, 
2008).  This information is presented graphically in the last column that takes the 
form of a forest plot.  A forest plot looks like a series of horizontal lines, with 
different sizes of ‘blocks’ intersecting the line.  The horizontal lines either 
intersect, or do not touch a solid vertical line that represents the ‘null effect’.  A 
plot is presented for the effect estimates and confidence intervals for each study, 
and then in the final row for the meta-analysis.  The CI is depicted by the 
horizontal line, and the point estimate of intervention effect is represented by the 
block on the line.  The size of the area of the square block is commonly referred to 
as the ‘size of the trial’, and indicates the weight of that specific study in the meta-
analysis, with a larger block representing a bigger weight.  Generally, studies with 
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a smaller CI will carry more weight. In the final row of this column a diamond is 
used to represent the CI for the totals of the meta-analyses.  
 
 
 
3.15.2   Continuous data 
 
For continuous data the inverse variance statistical method with fixed effect 
analysis model and mean difference effect measure were used.  The fixed effect 
model is based on the assumptions that all studies are measuring the same 
underlying effect and that any variability between studies is due to chance.  The 
limitation of this approach is that it may over-estimate precision (SA Cochrane 
Centre, 2008).  In the case of continuous data the second and third columns 
display the mean, standard deviation, and sample size for the natural medicine and 
placebo groups respectively.  The next column presents the weight that each study 
(in percentage form) contributed to the overall analysis.  Thereafter, the difference 
between the means of each group is presented, as well as the confidence limits.  A 
positive difference indicates that the natural medicine group tended to score 
higher on the outcome variable than the placebo group, a negative score indicates 
that the natural medicine group tended to score lower than the control, and a score 
of approximately zero indicates that there is no significant difference between the 
natural medicine and placebo groups in regard to the measured outcome.  These 
results are then represented in the next column in the form of forest plots as 
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described earlier (Fahey, Griffiths & Peters, 1995, Guyatt, et al., 1995 cited by 
Boltman, 2005).  
 
 
 
3.16  Characteristics of included studies 
 
The characteristics of the included studies were divided into the following 
subtitles: identifiers of the study (including author/s, title and year the article was 
published), an explanation of the methods used, the participants, interventions, 
outcomes, and allocation or concealment were stated, followed by additional 
notes.   
 
 
Included studies were divided into two groups: 
 
Comparison 01:  Post-breast cancer group (only studies that their sample 
consisted on post-breast cancer patient). 
 
Comparison 02: Post-cancer group (only studies that included post-breast cancer 
participants as part of their sample). 
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Table 3.2   
Comparison 01: Post-breast cancer group (Cluzan et al., 1996) 
Study ID 
Cluzan (1996).  Treatment of secondary lymphedema of the upper 
limb with CYCLO 3 FORT. 
Methods Double-blind placebo-controlled randomised trial. 
Participants 
Fifty seven adult women (>18 years of age) with secondary 
lymphedema of the upper limb after radiotherapy or surgery for breast 
cancer were included in this study.  Patients who had more than 2cm 
but less than 8 cm on at least one measuring point were eligible for 
this study.  Lymphoedema was classified as mild (between 2cm to 5 
cm) or moderate (between 5cm to 8cm).  Each of those groups were 
randomized.  Patients who present with any of the following were 
excluded: recurrent cancer, systemic or cutaneous infection, diabetes 
mellitus or heart, renal or hepatic failure, morbidity obese.  No 
additional drugs intakes were allowed to be taken by the patients 
during the period of this study. 
Interventions 
Each patient received 3 capsules of CYCLO 3 FORT (each capsule 
containing 150mg of Methyl Hesperidin Chalcone plus 150mg Ruscus 
Aculeatus extract plus 100mg of ascorbic acid), or placebo, 3 times a 
day. 
Outcomes 
The main outcome was swelling reduction in terms of the volume of 
oedema.  Secondary outcome consisted of subjective improvement 
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(recorded on a visual analogue scale, taking into account the mobility 
of the affected limb, feeling of heaviness and softness), as assessed by 
both the patient and investigator.  These outcomes were evaluated on 
day zero, day 30, day 60, and day 90. 
Notes 
CYCLO 3 FORT and placebo presented with an identical appearance. 
The patients were asked to returned surplus capsules at each visit in 
order to assess compliance with treatment.  
CLYCLO 3 FORT is composed of an extract of Ruscus (Butcher’s 
broom) plus Hesperidin Methyl Chalcone (found in citrus such as 
orange) plus ascorbic acid. 
 
 
Table 3.3  
Comparison 01: Post-breast cancer group (Gothard et al., 2004) 
Study ID 
Gothard (2004). Double-blind placebo-controlled randomised trial 
of vitamin E and pentoxifylline in patients with chronic arm 
lymphoedema and fibrosis after surgery and radiotherapy for 
breast cancer.  
Methods Randomized, doubled-blind controlled study. 
Participants 
Sixty eight volunteers (67 women and one man) between the ages of 
37 and 87, presenting with ipsilateral arm lymphoedema following the 
treatment for breast cancer, having a 20% or more increase in arm 
 
 
 
 
Chapter 3 77
volume, previous radiotherapy treatment to the breast/chest wall as 
well as axilla and/or supraclavicular fossa, without cancer recurrence.  
Out of the 68 volunteers, 33 participants had wide local excision as 
part of their primary treatment for breast cancer, 24 had some form of 
axillary surgery as well.  Thirty three underwent mastectomy and two 
had no primary surgery. 
Interventions 
Thirty five participants were allocated as the treatment group and 
received 500mg of dl-alpha tocopheryl acetate (vitamin E) twice a day 
orally as well as 400mg of pentoxifylline twice a day orally for 6 
months.  Thirty three participants were allocated into the placebo 
group and received a placebo as treatment.  Both groups were 
assessed at the beginning of the trial, at six months, and then at 12 
months. 
Outcomes 
Changes in volume of the affected upper limb, function and quality of 
life. 
Notes 
Pre-treatment baseline assessments included measurement of arm 
volume using a perometer, clinical assessment of subcutaneous 
induration within the radiotherapy volume, clinical photographs and 
patient self-assessments using the EORTC Quality of Life 
Questionnaires QLC-C30 and BR23 and were repeated at six and 12 
months.  Blood samples were collected at baseline and 1-2 weeks 
before the end of six months therapy.  Sixty three volunteers 
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completed their trial. 
 
 
Table 3.4 
Comparison 02: post-cancer group (Barclay et al., 2006) 
Study ID 
Barclay (2006). Reducing the symptoms of lymphoedema: is there 
a role for aromatherapy? 
Methods Randomized trial. 
Participants 
The sample used was composed of 81 adult patients (25-80 years old).  
The sample consisted of seventy seven women and four men.  Of the 
women, sixty one presented with arm lymphoedema and twenty with 
lower limb lymphoedema.  The participants had at least one year’s 
history of symptomology, were clinically diagnosed with bilateral or 
unilateral stable lymphoedema of the limbs with no evidence of acute 
inflammation, thrombosis or recurrence.  They had to be able to self-
massage their affected limbs and avoid any other aromatherapy or 
other treatment products during the length of the study.  The 
participants were in the maintenance phase of their lymphoedema 
treatment and did not receive therapy throughout this trial treatment.  
Forty patients were allocated to the aromatherapy intervention, there 
was one withdrawal so 39 received the intervention and one 
discontinue thereafter.  Forty one were allocated the placebo cream 
but 40 received the cream, four discontinued thereafter.  These 
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patients had been referred to the Dorset Cancer Centre lymphoedema 
service. 
Interventions 
Randomized participants received one of two creams immediately 
after randomization concluded.  The intervention cream contained 
wheat-germ oil with fennel, sage, geranium, black pepper and juniper 
essential oils in a base cream.  The placebo cream consisted of a 
simple base cream containing wheat-germ oil.  All patients performed 
daily simple lymphatic drainage and limb massage instructed by a 
lymphoedema specialist.  Exercise and skin care were advised for all 
patients and to continue the use of compression garments if indicated. 
Outcomes 
To assess the effectiveness, in terms of an objective reduction in limb 
volume and patient-reported symptom improvement and well-being, 
of simple lymphatic drainage and skin care/hydration by self-limb 
massage using a base cream containing aromatherapy oils versus a 
base cream alone. 
Notes 
Limb volume circumferences was measured from a standardized start 
point measured at 4cm segments using a self-tensioning tape measure 
and recorded as an absolute volume (ml).  Measurements were 
recorded monthly for three months.  Symptom improvement, activity 
and well-being were measured using the ‘Measure Yourself Medical 
Outcome Profile 2’ (MYMOP2).  This took place at the same time as 
limb volume measurement. 
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Table 3.5 
Comparison 02: post-cancer group (Micke et al., 2003) 
Study ID Micke (2003). Selenium in the treatment of radiation-associated 
secondary lymphedema.  
Methods Clinical trial. 
 
 
 
 
Participants 
A total of 48 patients (17 females and 31 males) with persistent, 
extensive or progressive lymphoedema between the ages of 34 to 93 
years old (median of 54 years) participated in this study.  Twelve of 
the patients presented with arm lymphedema and 36 with 
lymphoedema of the head and neck.  Of the 12 patients with arm 
lymphoedema, seven had oedema of the upper extremities after 
mastectomy plus axillary dissection and five due to breast conserving 
therapy plus axillary dissection.  All patients had radiotherapy 
previously. 
 
Interventions 
All patients received 350 ug/m2 body surface of sodium selenite 
(Selenase, biosyn Arzeimittel GmbH Fellbach, Germany) p.o. daily 
(generally giving a total dose of 500ug per day) over 4 to 6 weeks. 
Outcomes To evaluate the impact of selenium in the treatment of lymphoedema 
after radiotherapy. 
Notes No patient received additional anti-oedematous medication such as 
steroids or benzopyrones. 
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3.17  Excluded studies 
 
Four studies were excluded.  The reason for their exclusion for each study is given 
under their notes section.  
 
 
Table 3.6 
Excluded studies (Hutson et al., 2004) 
Study ID 
Hutson (2004a).  Horse chestnut seed extract for the treatment of 
arm lymphedema.  
Methods Double-blind, randomized, and placebo-controlled study. 
 
Participants 
Twenty five participants.  Eligible participants had stable arm 
lymphoedema and have affected: unaffected arm oedema ratios of > 
1.1 to 1 by bioelectric impedance, and significant response was 
empirically set as a 15% decrease in arm ratios. 
 
Interventions 
Placebo or horse chestnut seed extract (50mg escins) twice daily 
orally for three months, followed by a one month washout. 
Outcomes Reduction of arm volume. 
 
Notes 
Reason for exclusion: A full text article has not been published up to 
date, only an abstract is available.  According to a personal 
communication with the corresponding author, an article will not be 
published and they did not find dramatic benefits using horse chestnut 
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seed extract. 
 
 
Table 3.7 
Excluded studies (Kirshbaum, 1996) 
Study ID Kirshbaum. (1996). Using massage in the relief of lymphoedema.  
Methods Case study (semi-structure interviews). 
Participants 
Eight women who had attended at least six sessions of aromatherapy 
massage using lavender oil in the breast unit. 
Interventions Interviews post- aromatherapy massage using lavender oil. 
 
Outcomes 
To find out the benefits that a patient receive from the lymphoedema 
massage and to discover out if nursing time spent on massage is 
justified. 
Notes 
Reason for exclusion: The research method of this study did not meet 
the selection criteria. 
 
 
Table 3.8 
Excluded studies (Hutson, 2004) 
Study ID 
Hutson (2004b). Pycnogenol for the treatment of lymphedema of 
the arm in breast cancer survivors.  
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Methods Double-blind, placebo-controlled trial 
Participants Post-breast cancer lymphoedema patients. 
Interventions 
Pycnogenol (an extract of the bark of the French maritime pine tree) 
or corresponding placebo. 
Outcomes Arm volume reduction and improvement of symptoms. 
 
Notes 
Reason for exclusion: data has not been published up to date and 
according to a personal communication with the corresponding 
author, will not be published and they did not find dramatic benefits 
using pycnogenol. 
 
 
Table 3.9 
Excluded studies (Kasseroller, 1997) 
Study ID Kasseroller (1997).  Administration of selenium in lymphedema.  
Methods Randomized, double-blind placebo-controlled trial. 
Participants 
Post-breast cancer patients that developed lymphoedema after a 
mastectomy or Wertheim-operation. 
Interventions 
Sodium selenium given orally combined with decongestive physical 
therapy.  The length of the intervention was three months and three 
weeks. 
Outcomes Reduction of arm volume of the affected limb and improvement of 
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symptoms such as increase mobility and heat. 
Notes 
Reason for exclusion: article was not available through inter-library 
loan and could not be found available to the reviewer. 
 
 
 
3.18  Summary 
 
As systematic reviews are recognized as one of the most valuable and reliable 
research tools to aid the practice of evidence-based health care (Sleep & Clark, 
1999; Lemmer, Grellier & Steven, 1999 cited by Muntanga, 2004), this chapter 
explored the design and methodology for this systematic review.  Furthermore, 
this chapter also describes how primary studies were chosen to form part of this 
systematic review.  Four studies were selected for inclusion and were divided into 
two comparison groups; 1. post-breast cancer patients and 2. post-cancer patients.  
These studies were the only studies available in the field at this moment in time. 
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CHAPTER FOUR 
Results 
 
4.1  Introduction 
 
Four research articles met the inclusion criteria and were meta-analysed for the 
purpose of this systematic review.  Outcomes such as: perceived improvement in 
the domain of life style (this included any physical signs and symptoms related to 
the condition such as heaviness, tightness, pain, ache, itch, mobility of affected 
arm, and skin texture, as well as psychological symptoms like distress), changes 
in arm volume (of the affected limb), adverse effects, modification or cessation of 
treatment were analysed as continuous or dichotomous data, depending on the 
type of data that was used in the studies.  For dichotomous data the Mantel-
Haenszel statistical method using a fixed effect model and Risk Ration (RR) 
effect measure were used.  For continuous data the inverse variance statistical 
method with fixed effect analysis model and mean difference effect measure were 
used.  The perceptible change in limb volume outcome was analyzed as 
continuous data.  The analysis was conducted using the Review Manager 5 
(RevMan 5) software and presented in narrative form where RevMan 5 was not 
appropriate for use.  
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The four studies that met the selection criteria for this review are the following: 
 
• Gothard (2004) 
• Cluzan (1996) 
• Barclay (2005) 
• Micke (2003) 
 
 
The analysis was done within two main comparison groups: 
 
Comparison 01: Post-breast cancer lymphoedema group (composed of 
studies that use as part of their sample only post-breast cancer lymphoedema 
patients). 
 
Comparison 02: Post-cancer lymphoedema group (composed of studies that 
use as part of their sample post-breast cancer lymphoedema patients). 
 
 
The results for individual outcomes are displayed as forest graphs.  A narrative 
summary of relevant data is provided for results whose data were not appropriate 
to be entered into RevMan 5, lacked some type of numerical data, or that did not 
compare a treatment with something else such as placebo.  
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4.2 Life style improvement 
 
Life style improvement involved general symptom improvement, improvement 
specifically concerning the induration of fibrosis symptoms, well-being, and 
indicators such as softness, heaviness, mobility, and overall arm quality.  Results 
of life style improvement are presented separately for post-breast cancer patients 
and post-cancer patients. 
 
 
 
4.2.1  Comparison 01: Post-breast cancer group. 
 
The results of the comparison between vitamin E plus pentoxifylline versus 
placebo in the post-breast cancer comparison group regarding changes in 
induration of fibrosis, showed favour towards the vitamin E plus pentoxifylline 
(experimental) group in terms of presenting an improvement of the induration 
fibrosis of lymphoedema patients.  However, this result is not statistically 
significant (p = 0.68).  This result is graphically represented in figure 4.1 
 
Study or Subgroup
Gothard (2004)
Total (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
Events
6
6
Total
31
31
Events
8
8
Total
34
34
Weight
100.0%
100.0%
M-H, Fixed, 95% CI
0.82 [0.32, 2.11]
0.82 [0.32, 2.11]
Natural Medicines Placebo Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours experimental Favours control  
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Figure 4.1:  Forest plot of comparison 01: changes in induration fibrosis using 
vitamin E plus pentoxifylline.  
 
 
Cluzan, et al., (1996), using CYCLO 3 FORT, reported the following symptoms 
improvement after 3 months of treatment:  
 
 
Table 4.1 
Symptom improvement using CYCLO 3 FORT (Cluzan et al., 1996). 
 
Outcomes 
Natural Medicine Placebo 
Improvement 
% 
No. 
participants 
Improvement 
% 
No. 
participants 
Softness 11.56% 27 -5.07% 30 
Heaviness 32.78% 27 5.26 30 
Mobility 33.62% 27 -1.93 30 
Overall arm 
quality 
(patient) 
 
69.5% 
 
27 
 
32% 
 
30 
Overall arm 
quality 
(investigator) 
 
73.9% 
 
27 
 
20% 
 
30 
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4.2.2  Comparison 02: Post-cancer group 
 
The results of the comparison between aromatherapy cream versus placebo cream 
in the post-cancer comparison group regarding symptom improvement, shows 
favour towards the aromatherapy (experimental) group in terms of presenting an 
improvement of symptoms in lymphoedema experienced by the patients.  
However, this result is not statistically significant (p = 0.75).  This result is 
graphically represented in figure 4.2 
 
Study or Subgroup
Barclay 2005
Total (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
Mean
1.7
SD
1.4
Total
38
38
Mean
1.8
SD
1.3
Total
37
37
Weight
100.0%
100.0%
IV, Fixed, 95% CI
-0.10 [-0.71, 0.51]
-0.10 [-0.71, 0.51]
Natural Medicine Placebo Mean Difference Mean Difference
IV, Fixed, 95% CI
-1 -0.5 0 0.5 1
Favours experimental Favours control  
Figure 4.2: Forest plot of comparison 02: symptom improvement using 
aromatherapy cream. 
 
 
The results of the comparison between aromatherapy cream versus placebo cream 
in the post-cancer comparison group regarding well-being, showed favour towards 
the placebo (control) group implying a worsening in terms of well-being of the 
patients while using aromatherapy.  However, this result was not statistically 
significant (p = 0.74).  This result is graphically represented in figure 4.3 below: 
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Study or Subgroup
Barclay 2005
Total (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
Mean
1.5
SD
1.3
Total
38
38
Mean
1.4
SD
1.3
Total
37
37
Weight
100.0%
100.0%
IV, Fixed, 95% CI
0.10 [-0.49, 0.69]
0.10 [-0.49, 0.69]
Natural Medicine Placebo Mean Difference Mean Difference
IV, Fixed, 95% CI
-1 -0.5 0 0.5 1
Favours experimental Favours control  
Figure 4.3: Forest plot of comparison 02: well-being using aromatherapy 
cream. 
 
 
 
4.3  Changes in arm volume (of the affected limb). 
 
The results that dealt with changes in arm volume are presented separately for 
post-breast cancer group and post-cancer group, with separate results given for 
three months, six months, and 12 months where available.  None of the data had 
an appropriate format for analysis in RevMan 5; therefore they are presented in 
narrative format. 
 
 
 
4.3.1  Comparison 01: Post-breast cancer group. 
 
Cluzan, et al., (1996), using CYCLO 3 FORT, recorded a 12.9% significant 
reduction of arm oedema from baseline to 3 months for the experimental group 
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compared with a 2.55% increase of arm oedema for the control group.  These 
results were statistically significant (p = 0.009). 
 
 
Gothard, et al., (2004) results of the comparison between vitamin E plus 
pentoxifylline versus placebo in the post-breast cancer comparison group 
regarding changes in arm volume after 6 months, showed a slight favour towards 
the vitamin E plus pentoxifylline in terms of presenting a decreased in arm 
volume of lymphoedema patients after 6 months of treatment of 2.25% (SD = 
15.4) compared with a reduction of 1.12% (SD = 7.74) in the placebo (control) 
group.  However, the authors reported that this result was not statistically 
significant. 
 
 
Gothard, et al., (2004) results of the comparison between vitamin E plus 
pentoxifylline versus placebo in the post-breast cancer comparison group 
regarding changes in arm volume after 12 months, showed a slight favour towards 
the vitamin E plus pentoxifylline in terms of presenting a decreased in arm 
volume of lymphoedema patients after 12 months of treatment of 2.5% (SD = 8.0) 
compared with a reduction of 1.2% (SD = 10.9) in the placebo (control) group.  
However, the authors reported that these results were not statistically significant 
either.  
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4.3.2  Comparison 02: Post-cancer group 
 
Micke, et al., (2003), in the clinical trial using oral sodium selenite, reported a 
significant reduction of arm oedema in 83% of their participants.  
 
 
Barclay et al., (2006), using aromatherapy, reported a reduction of oedema in 69% 
of their participants compared with 57% from the placebo group.  However, 
results were not statistically significant (p = 0.38). 
 
 
 
4.4  Adverse effects 
 
The results dealing with the adverse effects of either experimental or control 
treatments are presented for comparison 01: post-breast cancer group, comparison 
02: post-cancer group, and then a combined meta-analysis was provided.  Where 
data were not in an appropriate format for analysis in RevMan 5, the results are 
presented in narrative format. 
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4.4.1  Comparison 01: Post-breast cancer group. 
 
The results of the comparison between vitamin E plus pentoxifylline or CYCLO 3 
FORT versus placebo in the post-breast cancer comparison group regarding 
adverse effects showed no favour towards neither the experimental or control 
group in terms of adverse effects.  However, these results are not statistically 
significant (p = 0.91).  Results are graphically represented in figure 4.4 below: 
 
Study or Subgroup
Cluzan 1996
Gothard (2004)
Total (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
Events
2
0
2
Total
27
35
62
Events
2
0
2
Total
30
33
63
Weight
100.0%
100.0%
M-H, Fixed, 95% CI
1.11 [0.17, 7.35]
Not estimable
1.11 [0.17, 7.35]
Natural Medicines Placebo Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.001 0.1 1 10 1000
Favours Natural Medicines Favours Placebo or other  
Figure 4.4: Forest plot of comparison 01: Adverse effects using vitamin E plus 
pentoxifylline or CYCLO 3 FORT. 
 
 
 
4.4.2  Comparison 02: Post-cancer group. 
 
The results of the comparison between aromatherapy cream versus placebo in the 
post-cancer comparison group regarding adverse effects, showed favour towards 
the placebo (control) group implying an increase of adverse effect in patients 
using aromatherapy.  However, this result was not statistically significant (p = 
0.51).  This result is graphically represented in figure 4.5 below: 
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Study or Subgroup
Barclay 2005
Total (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Events
1
1
Total
38
38
Events
0
0
Total
37
37
Weight
100.0%
100.0%
M-H, Fixed, 95% CI
2.92 [0.12, 69.54]
2.92 [0.12, 69.54]
Natural Medicine Placebo Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.001 0.1 1 10 1000
Favours experimental Favours control  
Figure 4.5: Forest plot of comparison 02: Adverse effects using aromatherapy 
cream. 
 
 
Micke, et al., (2003), using sodium selenite, reported that none of the participants 
experienced side effects for this treatment.  
 
 
 
4.4.3 Comparison group 01 and 02 combined 
 
The results of the comparison between vitamin E plus pentoxifylline or CYCLO 3 
FORT or aromatherapy cream versus placebo in the post-breast cancer 
comparison group and post-cancer comparison group regarding adverse effects 
showed a slight favour towards the placebo (control) group implying an increase 
of adverse effect in patients using aromatherapy or vitamin E plus pentoxifylline 
(treatment) group.  However, these result were not statistically significant (p = 
0.61).  CYCLO 3 FORT presented no side effects for neither of the groups.  The 
results are graphically represented in figure 4.6 below: 
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Study or Subgroup
Barclay 2005
Cluzan 1996
Gothard (2004)
Total (95% CI)
Total events
Heterogeneity: Chi² = 0.27, df = 1 (P = 0.61); I² = 0%
Test for overall effect: Z = 0.49 (P = 0.62)
Events
1
2
0
3
Total
38
27
35
100
Events
0
2
0
2
Total
37
30
33
100
Weight
21.1%
78.9%
100.0%
M-H, Fixed, 95% CI
2.92 [0.12, 69.54]
1.11 [0.17, 7.35]
Not estimable
1.49 [0.30, 7.33]
Natural Medicines Placebo Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.001 0.1 1 10 1000
Favours experimental Favours control  
Figure 4.6: Forest plot of both comparison groups: adverse effects using 
vitamin E plus pentoxifylline or CYCLO 3 FORT or aromatherapy cream. 
 
 
 
4.5.   Modification or cessation of treatment 
 
The last set of results deal with the modification or cessation of treatment 
outcome.  These results are presented separately for the post-breast cancer group 
and post-cancer group.  Where data were not in an appropriate format for analysis 
in RevMan 5, the results are presented in narrative format. 
 
 
 
4.5.1  Comparison 01: Post-breast cancer group. 
 
The results of the comparison between vitamin E plus pentoxifylline or CYCLO 3 
FORT versus placebo in the post-breast cancer comparison group regarding 
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modification or cessation of treatment showed a slight favour towards the placebo 
(control) group implying an increase of modification or cessation of treatment in 
patients using vitamin E plus pentoxifylline or CYCLO 3 FORT.  However, the 
results were not statistically significant (p = 0.36).  The results are graphically 
represented in figure 4.7 below: 
 
Study or Subgroup
Cluzan 1996
Gothard (2004)
Total (95% CI)
Total events
Heterogeneity: Chi² = 0.82, df = 1 (P = 0.36); I² = 0%
Test for overall effect: Z = 0.40 (P = 0.69)
Events
4
3
7
Total
27
35
62
Events
5
1
6
Total
30
33
63
Weight
82.1%
17.9%
100.0%
M-H, Fixed, 95% CI
0.89 [0.27, 2.97]
2.83 [0.31, 25.85]
1.24 [0.44, 3.47]
Natural Medicines Placebo Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours control  
Figure 4.7: Forest plot of comparison 01: modification or cessation of 
treatment using vitamin E plus pentoxifylline or CLYCLO 3 FORT. 
 
 
 
4.5.2  Comparison 02: Post-cancer group. 
 
Barclay et al., (2006), using aromatherapy cream, reported that 5 participants 
discontinued this trial whereas Micke, et al., (2003), using sodium selenite, did 
not report any participant discontinuing this treatment.  
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4.6  Summary results 
 
After the data collection was completed, only four studies met the selection 
criteria and were included in this systematic review.  The sample sizes of these 
studies were small and the presentation of their data was heterogeneous making it 
infeasible to enter some of the data into RevMan 5 for meta-analysis.  Thus some 
of the data from these studies was meta-analyzed, while other data had to be 
presented in a narrative form.  Based on the data currently available a definite or 
conclusive recommendation regarding the efficacy or adverse effects of natural 
medicines for the treatment of post-breast cancer lymphoedema cannot be drawn.  
However, it seems that sodium selenite taken orally and CYCLO 3 FORT also 
taken orally used for post-breast cancer (and post-radiotherapy for sodium 
selenite) lymphoedema patients had a positive effect on reducing the oedema of 
the participants.  As these are the only two studies meeting the characteristics 
required for selection for this systematic review, conclusions drawn from their 
data should be treated as tentative even though their results were statistically 
significant.  Further research needs to be conducted to reinforce the effectiveness 
of these natural medicines.  The results of the other studies regarding life style 
improvement, changes in limb volume (of the affected limb), adverse effects, and 
modification or cessation of the treatment were not statistically significant; 
therefore, no effectiveness or adverse effects conclusions could be drawn from 
them.  The four studies that have been included into this systematic review still 
need to be replicated, thus their results must be viewed with caution. 
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CHAPTER FIVE 
Discussion 
 
5.1  Introduction 
 
Lymphoedema is a lifelong condition characterised by protein-rich oedema in a 
part of the body as a result of the accumulation of lymphatic fluid due to 
obstruction or abnormalities in the lymph nodes of the lymphatic system (Pratt, 
1956).  This condition may result from treatments for breast cancer, such as 
lymph node dissection, surgery and/or radiation and can be reduced in severity if 
detected early and treated.  However, it is generally under-reported and under 
treated (Marrs, 2007).  Presently there is no cure for cancer related lymphedema, 
but it can be effectively managed with the appropriate treatment (Liao et al., 
2004).  
 
 
Of all the treatment options currently available, Moseley, Carati and Piller (2006) 
conclude that complete decongestive therapy, manual lymphatic drainage, 
pneumatic pump, and laser therapy usually result in greater volume reductions.  
According to Myoung (2004), the most effective therapy currently used to treat 
lymphoedema seems to be complete decongestive therapy, if provided by well 
trained health practitioners. 
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Despite these options being available, a survey of the literature reveals that 
patients suffering from lymphoedema often report that their health providers and 
care givers are not well informed and trained regarding this condition (Ridner, 
2006).  The worldwide paucity in education and training on the symptoms and 
treatments of lymphoedema, leads to late diagnosis and inadequate treatment that 
is evident by the lack of treatment centres and certified lymphoedema therapists, 
and other professionals prepared to treat lymphoedema (Marrs, 2007).  
 
 
In the face of limited knowledge and options provided by health care 
practitioners, patients often turn to popular media for information on 
lymphoedema and treatment options.  Breast cancer patients often make use of 
alternative or complementary medicines in their treatment of lymphoedema 
symptoms, especially in cases with heavy swelling, despite a lack of supporting 
evidence based literature documenting its effectiveness (Ashikaga et al., 2002; 
Fouladbakhsh et al., 2005).  For this reason the present systematic review set out 
to collect and analyse all available empirical based literature on the effectiveness 
of natural medicines as part of the treatment of post-breast cancer lymphoedema. 
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5.2  Discussion 
 
The present study, following a rigorous search for primary studies dealing with 
natural medicines and their use in post-breast cancer lymphoedema, has 
confirmed the lack of evidence for the effectiveness of natural medicines.  Even 
though evidence-based research is lacking, patients suffering from this condition 
are making use of natural medicines, possibly due to the popular literature that is 
available, which is often unscientific and/or ambiguous (e.g. Bone, 2008; Brady, 
no date; Brady, 1996a; Brady, 1996b; Dharmananda, 2000; Herbs2000.com, 
2008; Lymphedema People, 2008a; Lymphedema People, 2008b; Medifocus 
Health, 2008; O’Connor, 2008 & Sims, 2006).  Thus, further studies are required 
to address the role of natural medicine interventions for post-breast cancer 
lymphoedema, alone or in combination with other treatment modalities.  
 
 
Four research articles met the inclusion criteria and were meta-analysed for the 
purpose of this systematic review.  The primary objective of this systematic 
review was to assess the effectiveness of natural medicines on post-breast cancer 
lymphoedema treatment outcomes such as perceived improvement in the domain 
of life style (this included any physical signs and symptoms related to the 
condition such as heaviness, tightness, pain, ache, itch, mobility of affected arm, 
and skin texture, as well as psychological symptoms like distress), changes in arm 
volume (of the affected limb), adverse effects, and modification or cessation of 
treatment were analysed.  The sample sizes of these studies were small and only 
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some of the data was meta-analysed as the presentation of their data was 
heterogeneous, while other data had to be presented in a narrative form.   
 
 
Concerning the outcomes mentioned above, life style improvement, adverse 
effects, and modification or cessation of treatment were not significantly impacted 
by either 1) aromatherapy using an intervention cream containing wheat germ oil 
and essential oils of fennel, sage, geranium, black pepper and juniper; 2) CYCLO 
3 FORT taken orally; 3) sodium selenite ampules taken orraly; or 4) vitamin E 
plus pentoxifylline supplements also taken orally when compared to a placebo.  
On the other hand, changes in arm volume (of the affected limb) were 
significantly greater for post-breast cancer patients undergoing sodium selenite 
post-radiotherapy treatment or CYCLO 3 FORT treatment when compared to 
patients receiving placebo.  As these results are drawn from only two studies that 
met the characteristics required for selection for this systematic review, 
conclusions drawn from their data need to be confirmed through replication even 
though their results were statistically significant.  To sum up, although CYCLO 3 
FORT taken orally and sodium selenite also taken orally do seem to offer some 
benefit in reducing arm oedema, further research needs to be conducted to 
reinforce the effectiveness of these natural medicines.   
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5.3  Implications for practice 
 
Radina et al., (2004) argue that lymphoedema incidence is so high in part because 
most health care providers do not receive appropriate, formal training about the 
risk of lymphoedema, risk reduction, and treatment.  Quality nursing care has a 
big impact on patient’s outcomes in regard to lymphoedema.  Nurses can be 
proactive in patient education, thus they should have the appropriate knowledge 
about lymphoedema.  Due to the increasing attention being paid to 
complementary and alternative medicine (Gaskil, 2001), nurses are obliged to 
become more knowledgeable regarding natural medicines and therapies in order 
to evaluate their use, and educate patients (Mick, 2008).  
 
 
Health care professionals working in wards such as breast cancer units should 
especially be informed about this condition.  They should be encouraged to create 
awareness and counsel women that have undergone treatment for breast cancer 
about the risks and possible long-term problems such as lymphoedema that could 
develop after the intervention.  This will allow patients to be more involved in 
identifying this condition early on, and thereby seeking treatment in the early 
stages of lymphoedema.  Health care providers should be aware that natural 
medicines are currently popular among patients, and they should for this reason 
become knowledgeable in this area so that they are able to orientate patients 
towards evidence-based natural medicines.  Patients should be cautioned against 
self-medicating based on information that they have assimilated from the popular 
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media as these sources are sometimes misleading in an attempt to make profit.  
Patients could end up spending large amounts of money on medicines that are 
unlikely to significantly reduce the symptoms of lymphoedema or prevent it from 
progressing to the next stage.  Patients need to know that once they start to 
experience signs and symptoms of lymphoedema, they need to seek treatment 
immediately as the volume of the affected limb is likely to continue to increase 
and the condition could progress. However, with the appropriate care consisting 
of manual lymphatic drainage in combination with the application of compression 
bandages, the condition can be managed and the swelling reduced. 
 
 
 
5.4  Implications for future research 
 
In light of the popularity of natural medicines among post-breast cancer 
lymphoedema patients, it is alarming to find that there are only four randomized 
controlled trials, quasi-randomized controlled trials, or clinical trials available in 
all the databases searched by the reviewer.  There is an obvious and great need for 
well-designed, methodologically sound primary studies required to address the 
role of natural medicine interventions for post-breast cancer lymphoedema, alone 
or in combination with other treatment modalities.  Studies that have been 
included in this systematic review need to be replicated, and at this time their 
results may only be viewed as tentative.  In addition, some of the proposed natural 
medicines in this systematic review have not been tested on patients with post-
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breast cancer lymphoedema.  Current results need to be confirmed and new 
studies need to be produced regarding natural medicines that could possibly aid in 
the treatment of lymphoedema.   
 
 
A number of factors limit the possibility of drawing rigorous conclusions from the 
available literature, and these limitations need to be addressed and taken into 
account whenever researchers conduct and report on clinical trials.  Firstly, those 
studies that are available dealing with the treatment of lymphoedema seldom 
report the various treatment options available, or physiological mechanisms.  This 
kind of information is important not only for the purposes of comparison between 
one trial and another, but also for health care providers seeking information 
regarding clinical application.  Secondly, the sample sizes of these studies were 
small and the presentation of their data was heterogeneous making it infeasible to 
enter some of the data into RevMan 5 for meta-analysis.  Even though the 
included studies represent the best contemporary evidence available on post-
breast cancer lymphoedema and its treatment with natural medicines, they tend to 
fall short of the standards and levels of quality typically sought after for 
systematic reviews.  Either authors need to make raw data available, or consistent 
standards for analysis and reporting need to be adhered to so that meta-analysis 
and comparisons can be effectively drawn up.  There needs to be consensus on 
clinically relevant outcomes to be measured, as well as how to define them in the 
prospective clinical trials.  In the future, researchers should take care to 
benchmark their operationalisation of outcomes such as life style improvements 
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(including signs and symptoms), changes in limb volume, adverse effects, and 
modification or cessation of treatment against other studies, and ensure there is 
consensus on how they choose to report their results and other related studies that 
have already been published.  Lastly, the reviewer noticed that research into 
specific natural medicines has been conducted but that the results of these studies 
will not be published as the specific treatments were not significant in improving 
the condition.  Failing to publish non-significant results in a biased pool of 
literature from which one may draw information.  It is very important that all 
research that has been done in this area is published, even if the results are not 
significant, as it is relevant for the public to know that certain natural medicines 
are not beneficial in treating their condition. 
 
 
 
5.5  Conclusion 
 
Contemporary evidence based research regarding natural medicines for the 
treatment of lymphoedema and lymphoedema in general is lacking.  Of the 
available randomized controlled trials, quasi-randomized controlled trials, and 
clinical trials, only four primary studies met the inclusion criteria for this 
systematic review.  The studies generally suffered from small sample sizes and 
varied somewhat in their operationalisation of outcomes and the format for 
presenting results, making meta-analysis very difficult.  The included studies 
suggest that sodium selenite taken orally and CYCLO 3 FORT also taken orally 
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are effective in the reduction of limb volume. On the other hand, based on the 
studies included in this review, it appears that aromatherapy using an intervention 
cream containing wheat germ oil and essential oils of fennel, sage, geranium, 
black pepper and juniper, and vitamin E plus pentoxifylline taken orally are not 
effective.  However, seeing as these results are drawn from single studies with 
heterogeneous outcome variables, they should be seen as tentative until they are 
confirmed by replication.  Thus, more research is needed to investigate the 
effectiveness of natural medicines, as well as research on lymphoedema in general 
to aid in the construction of new policies regarding the characteristics of this 
condition, its treatment and diagnosis.  Until such research is conducted and 
published there will remain “a great need to produce guidelines regarding the 
detection, treatment and support to improve the quality of life of patients living 
with this illness” (Hayes, 2008, p. 10). 
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APPENDICES 
Appendix 1: 
Data collection sheets 
 
DATA EXTRACTION FORM 
 
Study Identifier: 
 
Comparison group: 
Participants: 
 Ages: 
 Control group No.: 
 Experimental No.: 
 Loss to follow up: 
 Discontinued: 
 Total analyzed: 
Length of Treatment:  
Intervention: 
 Experimental: 
 Control: 
 Both: 
Method: 
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Outcomes: 
 1 
 2 
 3 
 4 
 5 
Tool of assessment: 
 
 
Inclusion criteria: 
 
 
Exclusion criteria: 
 
Other: 
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CONTINUOUS OUTCOMES 
 
DICHOTOMOUS OUTCOMES 
 
Dichotomous outcome 
measures 
Experimental Group 
 
Natural Medicines 
Control Group 
 
Placebo or routine 
Events 
(n) 
Total (N) 
Events 
(n) 
Total (N) 
1      
2      
3      
4      
5      
6      
7      
 
Continuous outcome 
measures 
Experimental 
Group 
 
Control Group 
 
Placebo or routine 
Mean 
(SD) 
Total (N) 
Mean 
(SD) 
Total (N) 
1      
2      
3      
 
 
 
 
